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Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune disease of the 
central nervous system that preferentially targets the optic nerves and spinal cord, leading to 
paralysis, blindness and death. Severe pain is a disabling component of the disease with up to 
91% of patients reporting pain that is classified as central neuropathic pain (CNP), which is 
often refractory to treatment commonly used for peripheral neuropathy. This dissertation is 
comprised of two parallel studies both meant to inform a large Phase III study.  
The first part involves a Phase II randomized single blinded, sham-controlled study 
proposes to evaluate the acceptability, feasibility, safety and efficacy of a novel technique 
called Scrambler Therapy for CNP treatment in patients with NMOSD. Scrambler is a non-
invasive pain modifying technique that utilizes transcutaneous electrical stimulation of 
nociceptive fibers with the intent of re-organizing maladaptive signaling pathways. It has 
been examined for treatment of peripheral neuropathy with favorable outcomes, but there 
exists little data for use in CNP. Twenty-two participants were recruited from the Johns 
Hopkins NMO Clinic and were eligible for inclusion if they had CNP rated at 4 or higher on 
an 11-point numeric rating scale (0-10). Participants were randomized 1:1 and blinded to 
undergo either Scrambler Therapy or sham daily for 10 days. The primary outcome was a 
significant reduction in pain following 10-day treatment in the Scrambler intervention versus 
sham arm. The secondary outcome was safety, acceptability and feasibility. Sustainability of 
effect was also be evaluated. As the first-ever interventional pain study in NMOSD, it sets the 
foundation for future work that focuses on alleviating the physical and emotional suffering of 
patients who have neuropathic pain. As the first known study to investigate use of Scrambler 




for central neuropathic pain treatment, it further acts as a model for other diseases, including 
multiple sclerosis, spinal cord injury and stroke. 
The second study involves a cross-sectional assessment of pain on co-occurring 
symptoms in patients with NMOSD, which include anxiety, depression and sleep disturbance, 
and the impact of pain on quality of life (QoL). This involves a convenience sampling of 72 
patients diagnosed with NMOSD who completed each of the following surveys to determine 
pain, health-related QoL, anxiety, depression and sleep disturbance, respectively: Brief Pain 
Inventory (BPI), Short Form-36 Health Inventory (SF-36), Neuro-QoL [Quality of Life in 
Neurological Disorders] Short Form v1.0 – Anxiety, Neuro-QoL Short Form v1.0 – 
Depression, and Neuro-QoL Short Form v1.0 - Sleep Disturbance. This study broadens the 
understanding of how intervening on pain can enhance QoL. 
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This dissertation contains five chapters. The first chapter provides background, theoretical 
underpinnings, significance, and specific aims. Chapter two (Manuscript 1) is a review of the 
current state of the science of central neuropathic pain treatment as it relates to quality of life 
outcomes. It is currently in press with Pain Management Nursing. Chapters three and four 
(Manuscripts 2 & 3) are data-based manuscripts. Chapter three has been submitted to 
Neurology and includes results and analyses from Aims 1 & 2 of the study. Chapter four has 
been submitted to Journal of Neurological Sciences and provides results and analyses from 
Aim 3. Chapter five summarizes findings and discusses implications for nursing practice and 
future research.  
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Chapter 1: Introduction to and Significance of Central Neuropathic Pain in 
Neuromyelitis Optica Spectrum Disorder 
Persistent pain is a common and often frustrating problem for patients and health care 
providers, affecting approximately 100 million U.S. adults and costing $500-635 billion 
annually, according to the Institute of Medicine Report from the Committee on Advancing 
Pain Research, Care, and Education (2011). While estimates are varied, central neuropathic 
pain (CNP) constitutes a large percentage of persistent pain, and is associated with worse 
health than is non-neuropathic pain (Cohen & Mao, 2014). Neuropathic pain from any 
etiology is characterized by agonizing burning, shooting or tingling sensation in the face, 
arms, torso and legs caused by nerve damage (Cohen & Mao, 2014; Dworkin et al., 2007). It 
is particularly difficult to treat with only 40-60% of people achieving even partial relief 
(Dworkin et al., 2007). CNP experienced by patients with neuromyelitis optica spectrum 
disorder (NMOSD) is particularly refractory to available treatments (Qian et al., 2012). 
NMOSD is a chronic relapsing autoimmune disease of the central nervous system that 
preferentially targets the optic nerves and spinal cord, leading to blindness, paralysis and 
death (Wingerchuk, Hogancamp, O'Brien, & Weinshenker, 1999). Pain is more prevalent in 
NMOSD than in most other neurological diseases with up to 91% of patients reporting CNP 
(Zhao, Mutch, Elsone, Nurmikko, & Jacob, 2014; Pellkofer et al., 2013; Kanamori et al., 
2011; Borsook, 2012). Spinal CNP typically presents weeks to months after the cord damage 
has occurred, long after the acute injury, and may be the result of secondary changes due to 
reorganization of damaged circuits of the somatosensory system (Sjolund, 2002). CNP occurs 
at and below the spinal cord lesion level, and can persist for years, decades or throughout the 
patient’s life. The impact of CNP on quality of life (QoL) is profound. Research in NMOSD 




has found that those patients with CNP experience depression, decreased enjoyment of life, 
and difficulty with ambulation (Zhao et al., 2014; Pellkofer et al., 2013; Mutch, Methley, 
Moore, & Jacob., 2014). NMOSD is a severely disabling disease and there remains a high 
unmet need for effective treatment of CNP, thus allowing for an opportunity for investigation. 
Epidemiology of Pain in Neuromyelitis Optica Spectrum Disorder 
 NMOSD is a rare disease disproportionately affecting non-Caucasians and females 
that causes recurrent inflammatory attacks that preferentially target the optic nerves and 
spinal cord, leading to blindness, paralysis and death (Mealy, Wingerchuk, Greenberg, & 
Levy, 2012; Oh & Levy, 2012; Wingerchuk et al., 1999). It affects approximately 4,000-
8,000 people in the United States, (Mealy et al., 2012) and has a worldwide prevalence 
estimated to be 0.52 to 4.4/100,000 (Marrie & Gryba, 2013). In contrast to multiple sclerosis 
(MS), a related CNS autoimmune disorder that primarily targets myelin, NMOSD causes 
irreparable neuronal cell death which leads to more severe disability and a poorer prognosis 
(Popescu & Lucchinetti, 2016). Historically, within 5 years of symptom onset, 60% of 
NMOSD patients were blind in at least one eye, 52% were weak in at least one limb requiring 
gait assistance and mortality was as high as 30% (Wingerchuk et al., 1999).  These grim 
outcomes have improved since the discovery of the highly-specific anti-aquaporin-4 (AQP-4) 
biomarker for NMOSD in 2004 which allows clinicians to diagnose patients early and treat 
correctly, such that the mortality rate is now down to seven percent (Mealy et al., 2018). Even 
so, NMOSD continues to cause more severe permanent disability compared to MS 
(Wingerchuk, Lennon, Pittock, Lucchinetti, & Weinshenker, 2006; Mealy et al., 2012). 
Though a rare disease, NMOSD is devastating for those who have it. 




Etiology of CNP in NMOSD 
Despite these devastating consequences of the disease, patients have reported that pain 
is among the most prevalent and debilitating symptom, impacting mood, mobility and quality 
of life (QoL) (Qian et al., 2012; Zhao et al., 2014; Kanamori et al., 2011; Hollinger et al., 
2016; Shi et al., 2016; Moore et al., 2016; Kong et al., 2016). In particular, central 
neuropathic pain (CNP) is pervasive, severe, intractable to treatment, and affects 62-91% of 
patients with NMOSD (Zhao et al., 2014; Pellkofer et al., 2013). CNP is described as 
distressing, persistent and incapacitating (Cohen & Mao, 2014; Dworkin et al., 2007). The 
presence of CNP in NMOSD is a direct consequence of targeted immune-mediated 
destruction of the spinal cord and may be influenced by lesion span and location: NMOSD 
lesions are generally transverse, involving both the central gray matter and dorsal horns 
(Figure 1). The dorsal horns are innervated by primary ascending fibers that convey sensory 
information to the brain (Zhao et al., 2014; Pellkofer et al., 2013; Bradl et al., 2014; Todd, 
2010). Damage to the central gray matter in NMOSD leads to astrocytic damage and tissue 
necrosis, thus disrupting sensory pain tracts going to and from the brain (Qian et al., 2012; 
Kanamori et al., 2011). As a consequence of ongoing spontaneous activity arising in the 
periphery, surviving neurons develop increased background activity and increased responses 
to ascending nerve impulses, including normally harmless tactile stimulation (Centonze, 
2014). An additional mechanism of CNP involves peripheral sensitization of non-myelinated 
ascending C fibers interpreted by the brain as persistent pain, a characteristic sign of an 
inflammatory process in the spinal cord (Pellkofer et al., 2013).  
Current Treatment of CNP 




Even with the increased awareness of the effects of persistent pain in patients with 
NMOSD, treatment is still lacking. Currently, there is no standard of care for CNP treatment. 
As with neuropathic pain from other etiologies, the most frequently-used medications for its 
treatment in NMOSD are anti-epileptics, antidepressants and non-steroidal anti-inflammatory 
agents. Descriptive studies in NMOSD recognized the inadequate effect of these medications, 
resulting in frequent breakthrough opioid use (Qian et al., 2012; Zhao et al., 2014). 
Consequently, doses and numbers of medications are often increased, causing side effects, 
particularly at higher doses, which are independently associated with fatigue (Pellkofer et al., 
2013). With growing awareness of the dangers of polypharmacy, exploring non-
pharmacologic interventions to use in combination with pharmacologic therapies broadens 
options for CNP treatment. Advancing alternative mechanisms for pain treatment, either in 
isolation or combined with pharmaceutical interventions, may allow for reduced medication 
dosing that does not exacerbate other symptoms with which the patient is already struggling. 
Randomized controlled trials have demonstrated efficacy of non-pharmacologic 
interventions for other pain conditions, and this work has been extended to SCI and MS 
populations for the treatment of CNP with interventions such as nerve stimulation, 
acupuncture, exercise and massage therapy (Widerstrom-Noga & Turk, 2003; Boldt et al., 
2014; Namjooyan, Ghanavati, Majdinasab, Jokari, & Janbozorgi., 2014). A novel technology 
called Scrambler therapy is a non-invasive pain modifying intervention that utilizes 
transcutaneous electrical stimulation of ascending C fibers with the intent of re-organizing 
maladaptive signaling pathways (Coyne, Wan, Dodson, Swainey, & Smith, 2013). This 
neuromodulatory therapy has been investigated for treatment of persistent peripheral 
neuropathic pain in several conditions including chemotherapy-induced neuropathy, post-




herpetic neuralgia and post-surgical neuropathic pain with promising results (Coyne et al., 
2013; Majithia et al., 2016; Lee et al., 2016; Pachman et al., 2015; Smith, Coyne, Parker, 
Dodson, & Ramakrishnan, 2010; Ko, Lee, & Lee, 2013; Marineo, Iorno, Gandini, Moschini, 
& Smith 2012). Patients report sustained relief after undergoing daily treatment sessions for 
10 consecutive weekdays (Majithia et al., 2016). The effect of Scrambler therapy on patients 
with persistent central neuropathic pain has not been systematically tested, despite anecdotal 
support for its use (D’Amato, Mealy, Erdek, Kozachik, & Smith, 2018; Mealy, Newsome, 
Kozachik, Levy, & Smith, 2018). Determining if Scrambler technology is an acceptable, 
feasible, and effective way to intervene on the pain experienced by those with NMOSD is the 
first step toward offering an enhanced QoL to functionally impaired patients (Zhao et al, 
2014; Mutch et al., 2014; Moore et al., 2016). Improving functional status and QoL may 
afford patients with opportunities to engage in richer lives socially, personally and 
professionally in the context of significant pain reduction, and Scrambler potentially enables 
this in a non-invasive way. This research provides a unique opportunity to advocate for 
patients by recognizing the impact symptoms have on quality of life and exploring 
remediation. 
Scrambler Therapy: potential application to central neuropathic pain 
 Scrambler therapy was granted approval by Food and Drug Administration (FDA) 
510(k), "Scrambler ST 5 TENS Device," (K081255) in February 2009 for acute, chronic and 
post-operative pain (https://www.accessdata.fda.gov/cdrh_docs/pdf8/K081255.pdf, 2009). 
Scrambler is a type of transcutaneous electrostimulation (TENS) that uses peripheral nerve 
stimulation to modify ascending sensory responses in the spinal cord. Electrical impulses are 
transmitted via surface electrodes placed surrounding the pain area (Figure 2). Traditional 




TENS units take advantage of the Gate Control Theory in which stimulation of surrounding 
A-delta fibers dampens incoming pain signals (Garrison & Foreman, 1994; Blivis, Haspel, 
Mannes, O'Donovan, & Iadarola, 2017). Scrambler therapy provides additional stimulation of 
ascending sensory C fibers that imitate normal nerve action potentials with the intent of re-
organizing maladaptive signaling pathways (Coyne et al., 2013). The theory behind 
Scrambler treatment is that “scrambled” waveforms – instead of repetitive identical 
waveforms in traditional TENS – are dynamically assembled into strings of information that 
are interpreted by the brain to replace pain with “no-pain” information (Majithia et al., 2016; 
Ricci et al., 2012). In contrast to traditional TENS therapy that provides only short-term pain 
relief, studies with Scrambler therapy in peripheral neuropathy suggest that patients can have 
significantly reduced pain or be pain-free for up to 3 months following a series of treatments, 
and that follow-up treatments may require fewer sessions for continued relief (Majithia et al., 
2016). 
 Use of Scrambler therapy for neuropathic pain management has been reported in 28 
peer-reviewed articles in peripheral neuropathic pain syndromes (Majithia et al., 2016; Smith, 
Cheville, Loprinzi, & Longo-Schoberlein, 2017; Joo, Cho, Cho, Kym, & Seo, 2017; Park et 
al., 2017; Kim, Lee, & Lee, 2017; Kashyap, Joshi, Vig, Singh, & Bhatnagar, 2017; Smith, 
Auwaerter, Knowlton, Saylor, & McArthur, 2017). In the largest sample to date (n=226), 
80% of patients had a greater than 50% reduction in pain in a prospective, open-label trial 
(Sabato, Marineo, & Gatti, 2005). The most studied condition has been chemotherapy-
induced neuropathy and other cancer-related pain (Lee et al., 2016; Pachman et al., 2015; 
Coyne et al., 2013; Smith et al., 2010; Ricci et al., 2012; Park et al., 2013; Notaro et al., 
2016), where Scrambler has provided significant pain reduction in all but one randomized 




study which found no difference in a small sample size (n=14) (Campbell et al., 2013). The 
only other trial conducted with an equally rigorous prospective double-blinded placebo-
controlled design was for the diagnosis of low back pain (n=30) where the treatment group 
was found to have a significant reduction in pain compared to the control group 
(Starkweather et al., 2015). No serious adverse events have been reported related to treatment 
with Scrambler therapy (Majithia et al., 2016). In central neuropathic pain, the damaged 
neurological circuits reside in the spinal cord rather than the peripheral nerve. However, the 
stimulation via electrodes is to dermatomes that correspond to intact spinal cord tissue, on 
which the Gate Control Theory and Scrambler mechanisms are thought to act. 
NMOSD as a Translational Model for Treatment of CNP from other Causes 
NMOSD is an ideal disease in which to test a proof-of-concept intervention for pain. 
First, there remains a significant unmet need for pain treatment in NMOSD as current 
medical and non-medical interventions have had little impact (Zhao et al., 2014). Second, the 
severe pain associated with NMOSD allows for even subtle improvements to be detectable. 
The damaged spinal cord circuits in NMOSD are similar to the pathologies in related CNP 
etiologies including traumatic spinal cord injury and MS. If a tested treatment is found to be 
effective at improving CNP in the NMOSD patient population, it may also be useful in these 
related conditions. CNP is associated with worse overall health in all diseases, and is difficult 
to treat (Cohen & Mao, 2014; Dworkin et al., 2007). 
Specific Aims and Hypotheses 
 The aims for this study were as follows: 




Aim #1: To examine the safety, feasibility, acceptability and effectiveness of Scrambler 
therapy in treating central neuropathic pain in NMOSD. Hypothesis 1: Scrambler therapy is a 
safe, feasible, acceptable and effective intervention.  
• Sub-aim #1a: Feasibility of treatment was examined to determine whether the 
intervention was appropriate for this patient population, toward the effort of 
informing a larger, Phase III study. This was measured by assessing the following: 
1) adherence to visit schedule and 2) response to the following question asked 
directly after completion of the 10-day treatment period: “Do you think you 
received treatment?” (Yes/No). Acceptability was measured by assessing response 
to the following question, also asked directly following the treatment course: 
“Would you want to continue treatment in clinic, if available?” (Yes/No). 
• Sub-aim #1b: Safety was be measured based on a comparison of safety profiles in 
treatment versus sham arms. 
• Sub-aim #1b: Effectiveness was evaluated based on degree of improvement of 
pain using an 11-point Numeric Rating Scale (NRS) score in the treatment group 
compared to sham, with the primary outcome focused on end-of-treatment time 
point, and the secondary outcomes examined sustainability of effect at 30- and 60-
days following treatment.    
Aim #2: To assess the relationship between improved pain in response to Scrambler therapy 
and other co-occurring symptoms, including anxiety, depression and sleep disturbance, in 
patients with NMOSD.  Hypothesis 2: Impacting pain with Scrambler therapy will also 
improve some or all co-occurring symptoms. 




Aim #3: To investigate components of the symptom cluster in patients with NMOSD and the 
influence of pain on co-occurring symptoms and QoL. Hypothesis 3.1: Pain will be 
associated with QoL and co-occurring symptoms including anxiety, depression and sleep 
disturbance, in patients with NMOSD.  
Innovation 
First study to investigate an intervention for pain in patients with NMOSD 
Despite the significant unmet need in NMOSD, there have been no trials in this 
patient population investigating any pharmacologic or non-pharmacologic intervention for 
pain management in the United States. Given that most patients are currently on medications 
commonly used for peripheral neuropathic pain treatment, this proposal utilized a multimodal 
approach that combines a non-pharmacological intervention with more-established 
pharmacological agents. Targeting co-occurring symptoms using a multimodal approach 
(incorporating multiple interventions that have different mechanisms of action) may be more 
effective in improving symptoms, and consequently, QoL. A multimodal approach impacts 
QoL more robustly in comparison to a unimodal intervention in related autoimmune diseases 
of the central nervous system (Crayton & Rossman, 2006; Turcotte et al., 2015). The current 
proposal implements the multimodal use of Scrambler therapy added to a stable 
pharmacologic regimen to increase the likelihood of successfully treating pain and, in turn, 
positively impacting QoL.  
Scrambler Therapy is a novel, non-invasive approach for treatment of central 
neuropathic pain from any cause  




Despite the growing body of evidence to support efficacy of Scrambler, the utility of 
Scrambler therapy for treatment of CNP pain has never been systematically explored prior to 
this investigation. As in peripheral neuropathy, the expectation was that Scrambler therapy 
would act as a neuromodulator by providing new, non-painful sensory signals that replace the 
previous nociceptive signals, which get interpreted by the brain. Similar to how the brain 
interprets sensory impulses as pain after spinal cord damage occurs, neuroplasticity within the 
central nervous system enables retraining of that perception of pain so that the area of 
concern is no longer interpreted by the brain as painful. The Scrambler device has pre-market 
clearance through the FDA for acute, chronic and post-operative pain, and is not restricted to 
peripheral neuropathy (https://www.accessdata.fda.gov/cdrh_docs/pdf8/K081255.pdf, 2009). 
Preliminary Data 
Scrambler Therapy for Central Neuropathic Pain 
 We have recently treated and published results for two patients with central 
neuropathic pain with Scrambler: one with longstanding CNP as a consequence of a 
brainstem stroke (D’Amato et al., 2018), and the second with transverse myelitis (Mealy et 
al., in press). CNP in both patients was previously unresponsive to multiple neuropathic pain 
agents, and each underwent 10 days of Scrambler treatment. The patient with the brainstem 
stroke had a reduction in her pain from 9-10/10 to 0-0.5/10, and she was able to discontinue 
all pain medications. The patient with transverse myelitis is further described below in detail. 
In both cases, we started Scrambler treatment at Day 1 with electrodes placed above the 
affected dermatome (which corresponds to lesion level), and lowered channel-pairs daily as 
pain level declined down the body, corresponding to the spinal cord level. These two cases 




offer proof-of-concept for the treatment of CNP through Scrambler therapy and have 
informed the current proposal.   
Case presentation. A 65-year-old Caucasian woman with history of TM presented 
with long-standing central neuropathic pain. She was initially evaluated at an outside hospital 
in October 2013 for right hand paresthesias with accompanying neck pain followed by lower 
extremity weakness, right arm incoordination and weakness, urinary retention, torso band-
like tightness, and impaired ambulation. Progression to nadir developed over approximately 
24 hours. Neuroaxial imaging showed a C3-5 lesion on T2-weighted sagittal and axial 
sequences with mild ill-defined peripheral enhancement on post-gadolinium T1-weighted 
sequences (Figure 4). Mild stenosis and foraminal narrowing was noted, though 
flexion/extension X-rays indicated preserved cerebrospinal fluid signal surrounding the cord. 
No flow voids were noted. Given the MRI findings in the setting of symptoms attributable to 
the described lesion, presence of a sensory level, progression to nadir between 4 hours and 21 
days, the presence of oligoclonal bands, and a thorough autoimmune evaluation to rule out 
other causes, the diagnosis of TM was made in concordance with the TM Consortium 
Working Group diagnostic criteria (2002). Muscle and nerve conduction studies were 
conducted and were unremarkable. The patient underwent 5 days of high-dose corticosteroids 
with modest improvement in her neurologic status.   
 She presented to the Johns Hopkins Transverse Myelitis Center in April 2014 for a 
second opinion due to persistent weakness and severe neuropathic pain. Neurologic exam 
demonstrated diffuse hyperreflexia, mild left hip flexion weakness, and gait dysfunction. In 
depth interview revealed that her neuropathic pain (in her bilateral legs, and right arm and 
torso) was the most disabling aspect of her condition. She was on hydrocodone-




acetaminophen (5-300 mg every 6 hours as needed) and tramadol (50 mg every 4 hours as 
needed) prior to presenting to us which was only partially beneficial. Subsequently, she tried 
several other therapies that were ineffective, only partially helpful or caused intolerable side 
effects, including duloxetine (120 mg daily), gabapentin (900 mg three times daily), 
pregabalin (50 mg twice daily), nortriptyline (50 mg daily), capsaicin, topical lidocaine, 
meditation and acupuncture. In early 2017, she was offered Scrambler therapy for refractory 
pain treatment. At the time of Scrambler treatment, she was on duloxetine (120 mg) daily and 
topical lidocaine as needed. The patient received Scrambler therapy for 45 minutes daily over 
a period of 10 consecutive weekdays, the typical administration as delivered for other types 
of pain (Calmare Technologies Inc., 2008). Prior to initiation of Scrambler treatment, the 
patient reported a pain level of 5 out of 10 using an 11-point (0-10) numeric rating scale 
(NRS) in the morning, which would increase to an NRS pain level of 10 out of 10 by 
nighttime, as well as with exertion and stress. She had developed activity intolerance 
secondary to pain. The neuropathic pain was located in the regions mentioned above and she 
reported severe allodynia in her right upper extremity that interfered with her grip. Moreover, 
the pain interfered with sleep.   
 The stated purpose of Scrambler Therapy is to provide “non-pain” information to 
replace continued pain-generation impulses. To do this requires capturing the surface 
receptors of the C fibers (and perhaps other fibers) in the dermatome of the affected nerves. 
The placement is done to also avoid putting an electrode directly on an area of damaged nerve 
sensation. This patient’s worst pain was in the C-6,7,8 distribution and involved the distal 
arm to the axilla; she also had pain in the T-1, and L5 distribution. To begin, we placed sets 
of electrodes (“channels”) in the C6 and C8 dermatomes in an area of normal sensation, about 




8 inches apart, being careful to stay above the area of distal allodynia and pain (Figure 5). At 
end of Day 1 treatment, her NRS scale pain score decreased to 1 out of 10 and her allodynia 
was improved. By Day 2, the pain had returned to 3/10, but the pain/allodynia area had 
moved down the arm, such that we could treat with pairs of electrodes on C6, C7, T8 with the 
distal lead on the medial arm for C8, and L5 to L5. At end of Day 2 treatment, the score 
decreased to 1.5 out of 10, with resolution of banding sensation and shoulder/upper arm pain. 
On Day 3, her pain score started at 2 out of 10. All five channel-pairs of electrodes were used, 
each spanning across one of the following dermatomes: C6, C7, C8, T8 and L5. The patient 
continued with all five channel-pairs for the duration of treatment. Prior to beginning 
treatment on Day 4, her pain score was reported at 4 out of 10, and 0 out of 10 by end of 
treatment; of note, allodynia had completely resolved. Her pain continued to decline in 
severity and in location daily following each treatment, with the pain being nearly resolved 
by the end of Day 10 (Figure 6). The patient reported no adverse events.   
In the 30 days following Scrambler intervention, the patient’s pain remained 
improved, with a pain score of 2.5 out of 10. Furthermore, her sleep and activity intolerance 
improved. Over 90-day follow-up, her pain began to increase to pre-treatment levels. 
However, the patient reported that Scrambler therapy helped in reducing her pain more than 
any previous therapy and expressed a desire to receive another course of treatment.  
 Our patient experienced persistent central neuropathic pain for 3.5 years prior to 
Scrambler therapy and reported that this treatment improved her pain considerably more than 
previous pharmacologic and non-pharmacologic interventions. The patient further recounted 
that this treatment was tolerable, and no safety concerns have emerged in our patient or others 
treated with Scrambler (Majithia et al., 2016). Our patient’s re-emergence of pain at 




approximately 90 days, mirrors data from Scrambler use in peripheral neuropathic pain 
conditions. Observational research suggests that patients who receive subsequent treatments 
continue to respond to additional treatments, often with fewer treatments needed over time 
(Smith et al., 2017; Smith et al., 2017).  Scrambler therapy is an emerging non-invasive 
treatment that may be safe and effective for central neuropathic pain. Notably, most reports of 
Scrambler use have been observational, in which the impact of placebo effect could not be 
accounted, including in the current report. Nonetheless, this open-label case report supports 
comprehensive, well-controlled investigation of Scrambler therapy in MS, NMOSD and other 
disorders that cause refractory central neuropathic pain.  
Symptom co-occurrence in NMOSD and the effect on QoL 
A symptom cluster is a group of interrelated co-occurring symptoms in a given 
chronic disease (Kim, Abraham, & Malone, 2013). Recent research investigating symptom 
clusters in other chronic diseases suggests that treating one symptom among a cluster does 
not sufficiently improve QoL (Kim, et al.; 2013). The implication for NMOSD is that treating 
CNP in isolation may not be sufficient to improve QoL in the context of other debilitating 
symptoms including anxiety, depression and sleep disturbance. In MS, which presents with 
similar symptoms as in NMOSD, the complexity and interconnectedness of symptoms seems 
apparent in the research: pain has been shown to affect anxiety and depression, as well as 
QoL (Archibald et al.,1994; Alschuler, Jensen, & Ehde, 2012); sleep is an independent 
predictor of QoL (Merlino et al., 2009) and sleep difficulties exacerbate other MS symptoms 
(Manocchia, Keller, & Ware, 2001); sleep disruption may contribute to the development of 
depression (Krupp, Alvarez, LaRocca, & Scheinberg, 1988; Manocchia et al. 2001); pain 
impacts depression and is mediated by anxiety, sleep quality and fatigue (Amtmann et al. 




2015). This suggests that addressing one symptom may also impact other co-occurring 
symptoms. Drawing from the MS literature, if the presence of pain in NMOSD impacts 
depression, anxiety and sleep disturbance, then adequate treatment of pain could have an 
impact on these other symptoms. This may be particularly true in NMOSD, given that the 
pain is more severe than in MS and published data suggest that pain disproportionately 
impacts QoL in NMOSD as compared to other co-occurring symptoms (Mealy, Simpson, 
Levy, 2016; Mealy et al., 2017). 
In NMOSD, pain correlates with anxiety, depression and disability, and is associated 
with poorer QoL (Moore et al., 2016). Interestingly, poor QoL does not correlate with 
disability, anxiety or depression. Taken together, these findings support our own findings 
which suggest that, while symptom co-occurrence exists in NMOSD, adequate pain treatment 
may improve these symptoms and, in turn, QoL (Table 1). The evidence for co-occurrence of 
symptoms provides preliminary evidence for the need to explore the presence of a symptom 
cluster. Exploring the presence of a symptom cluster and the impact of pain on co-occurring 
symptoms may influence approaches to treatment in the future. The Theory of Unpleasant 
Symptoms (TOUS) provides the theoretical underpinning for such an analysis (Figure 3). 
TOUS postulates that co-occurring symptoms are both influenced by and influence 
physiologic, psychologic, and situational factors, with a combined or synergistic effect on the 
outcome (Lenz, Pugh, Milligan, Gift, & Suppe 1997). Analyzing the effect of pain treatment 
on QoL will offer providers more information about how to approach symptom management 
in this population.  
Measuring Pain in NMOSD 




 A number of measures that have been developed for pain assessment have been used 
for research in patients with neuroimmunologic disorders, particularly in MS, and include the 
Visual Analog Scale (Khan F, Amatya B, & Kesselring, 2013), Numeric Rating Scale (NRS; 
Svendsen, Jensen, & Bach, 2004), McGill Pain Questionnaire (MPQ; Silver, Blum, Grainger, 
Hammer, & Quessy, 2007) and the Brief Pain Inventory (BPI; Vollmer, Robinson, Risser, & 
Malcolm, 2014). However, the nature of the pain experienced by NMOSD patients is 
exceptional in its chronicity and intensity. Three pain instruments have been utilized to better 
elucidate our awareness of pain in NMOSD, the NRS (Qian et al., 2012; Pellkofer et al., 
2013; Araki et al., 2014; Ringelstein et al., 2015), MPQ (Qian et al., 2012) and BPI 
(Kanamori et al., 2011; Zhao et al., 2014) none of which has yet been validated for use in this 
population.  
Potential Application of Brief Pain Inventory in NMOSD 
A synthesis of the literature was performed to investigate clinical and research utility 
of the BPI, as well as evidence for reliability and validity of the measurement tool. 
Specifically, this synthesis aimed to describe the inception, development, reliability and 
validity of the BPI across diseases, and its use in nursing literature, with the singular purpose 
of assessing its applicability in NMOSD. A PUBMED search was conducted that specified 
“Brief Pain Inventory,” AND “reliability,” “validity” and/or “validation” in the title/abstract. 
Eighty-one articles were found that addressed reliability and validity of the instrument. 
Because of the focus of the current synthesis on NMOSD, only those validation studies that 
were pivotal to the tool’s inception and development and/or pertinent to use in NMOSD were 
included. For its use in nursing research, a broad search of the Cumulative Index of Nursing 
and Allied Health Literature (CINAHL) Plus database was conducted using the search term 




“Brief Pain Inventory” in all text and narrowing by “Nurse” as Any Author, which provided 
27 articles for review. Articles were not limited by date for either search. The BPI User Guide 
was additionally used as a reference. 
Description of BPI and current research. According to the Brief Pain Inventory 
User Guide, the BPI was originally conceptualized in the late 1970’s in response to the need 
for better capture of the severity and impact of cancer pain and as a way to quantify 
improvement in pain after changes to analgesic therapy were made (Cleeland 2009). This was 
an initiative of the National Cancer Institute (NCI) and World Health Organization (WHO), 
in response to growing awareness of the incapacitating pain associated with cancer. At the 
time, existing questionnaires including the MPQ mostly sought to assess nonmalignant pain 
and were thought to be too burdensome for patients suffering from severe intractable pain; 
they were lengthy, complex and included irrelevant items. Patients were asked what questions 
they felt were the most important for communicating their pain experience, and it became 
clear that no such tool existed. Supported by NCI and WHO, the Pain Research Group at the 
University of Wisconsin Medical School-Madison, under the direction of Charles S. 
Cleeland, PhD, planned a program to develop a self-report instrument that would be short, 
easily-understandable, could be self-administered, could be easily translated into other 
languages, and, importantly, would capture not only pain severity, but also the perception of 
how pain affected daily life. This group later became the Department of Symptom Research 
at The University of Texas MD Anderson Cancer Center (Cleeland., 2009).  
Several iterations of this instrument were attempted over the years to ensure that the 
tool captured the data intended by the group, in the way they intended to capture it, as 
outlined above. According to Cleeland (2009), the working group eventually came up with 




the BPI long form, followed by the short form. The BPI short form shortened the recall period 
from 7 days to 24 hours for question reference, and is generally the form that is being 
referenced when simply citing the “BPI”. It is comprised of front and back body diagrams, 
four pain severity items and seven pain interference items rated on 0–10 scales, and a 
question about percentage of pain relief by analgesics. Each section is first scored 
individually for the self-administered current version. The BPI assesses pain severity in four 
questions from pain at its “worst,” “least,” “average,” and “now” (current pain). Pain 
interference is measured among seven daily activities, including general activity, walking, 
work, mood, enjoyment of life, relations with others, and sleep. BPI pain interference is 
typically scored as the mean of the seven interference items. This mean can be used if more 
than 50%, or four of seven, of the total items have been completed on a given administration. 
While other items exist on this measurement tool, they are at this time supplemental and do 
not contribute to the scoring as they have not been validated or proven useful in the context of 
the tool as a whole. The fee for use is dependent on the intended use: unfunded academic 
research is able to obtain for free, $300 for funded academic research, and significantly more 
for commercial research at $2,000. Also, the language may influence price (Cleeland, 2009). 
Evidence of BPI reliability and validity. The BPI was initially devised for cancer 
pain and initial reliability and validity testing was performed in this English-speaking 
population; Cronbach’s alpha reliability ranges from 0.77 to 0.91 and test-retest reliability for 
ratings of pain “worst” (0.93) and “usual” or “average” pain (0.78) in patients with cancer 
was high, which signals acceptable reliability (Daut, Cleeland, & Flanery, 1983; Cleeland et 
al., 1994). As expected, test-retest reliability for pain “now” severity ratings were lower 
(0.59) since pain intensity changes over time (Daut et al., 1983). Exact validity testing 




performed in the initial English-speaking cancer pain patient sample could not be reported as 
only the abstract was available. However, the measurement tool has since been validated for 
use in peripheral neuropathy (Wu et al., 2007), chronic non-cancerous pain (Dworkin et al., 
2008), post-herpetic neuralgia in herpes zoster (Coplan et al., 2004), spinal cord injury (Bryce 
et al., 2007), inguinal pain following hernia repair (Franneby et al., 2008), osteoarthritis 
(Kapstad, Hanestad, Langeland, Rustoen, & Stavem, 2008), and cerebral palsy (Tyler, Jensen, 
Engel, & Schwartz 2002), to name several. Additionally, it has been validated 
psychometrically and linguistically in over 20 other languages and has been linguistically 
validated in another thirty (Cleeland, 2009). It has been proposed that the BPI should be 
utilized in all clinical trials involving chronic pain (Dworkin et al., 2008).  
Many studies in MS have used the BPI over the years (Osborne, Raichle, Jensen, 
Ehde, & Kraft, 2006; Newland, Naismith, & Ullione, 2009; Newland, Riley, Fearing, Neath, 
Gibson, 2009). Osborne et al. specifically addressed reliability and validity of this instrument 
in MS patients with chronic pain and aimed to examine psychometric properties of 
interference measures only (Osborne et al., 2006). As such, only the interference component 
of the BPI was utilized and was administered to MS patients by mail. The modified BPI 
interference scale demonstrated excellent internal consistency (α=0.93-0.96) as well as 
construct and concurrent validity, providing preliminary support for the reliability and 
validity of this modified scale for use in MS patients with chronic pain. Construct validity 
was assessed by factor analysis. The principal factor analysis examining the items from the 
modified 10-item version of the BPI Interference scale and the three pain intensity items also 
resulted in a two-factor solution that was rotated with direct oblimin. The first factor 
accounted for 64.6% of the variance and the second factor accounted for an additional 9.2% 




of the variance. All 10 interference items had high factor loadings on Factor 1 (range 0.59 to 
0.94) assessed by correlation analyses to examine the associations between the pain 
interference items and scale scores and the measures of pain intensity and psychological 
functioning. Pearson correlation coefficients indicate that the first seven items from the BPI 
Interference scale were each significantly associated with average pain intensity, with 
correlations ranging from 0.42 to 0.69. 
A study out of Turkey examined the psychometric properties of the BPI as well as its 
reliability, validity and discriminative utility for estimating the status of chronic pain in 
neuropathic and nociceptive pain (Erdemoglu & Koc, 2013). Patients with chronic pain were 
evaluated by a pain specialist and the etiology of their pain was determined to be either 
nociceptive or neuropathic. Test-retest was done for everyone, and no significant differences 
were found between the two tests within the nociceptive and neuropathic groups (Cronbach’s 
α for test=0.84 and retest=0.83). Cronbach’s α was performed for reliability testing of pain 
interference items, and the internal consistency between items was relatively high for all 
groups (7 items each for each of two groups, ranging from 0.61-0.81). Principal component 
analysis yielded three factors (severity scale, activity interference, and sleep and mood 
interference) which explained 70.68% of the variance for the nociceptive group and 66.48% 
for the neuropathic group. The component of the study, which utilized a composite score 
based on BPI and another pain measure, looked at differentiating pain. As nociceptive pain is 
not an important component of the pain syndrome found in NMOSD, this will not be reported 
for the purpose of this critique.  
Use in nursing research. Twenty-seven articles were found that involved nursing 
research utilization of the BPI. Not surprisingly, the bulk of nursing research explored 




different aspects of cancer pain (11 manuscripts). Another three manuscripts examined post-
operative pain, two looked at fibromyalgia, two addressed MS and the remaining nine each 
had one article on a variety of topics. None of these addressed validation of the measure in 
the given population and instead utilized the BPI to measure pain in their cohorts. Given the 
relevance to the topic at hand, a closer look was taken at the two MS studies. The first 
assessed pain, fatigue, depression, sleep disturbance and quality of life in women with MS 
compared with healthy controls (Newland et al., 2009). The researchers utilized the BPI-long 
form, in addition to the MPQ. While the study does not explicitly discuss the rationale for 
choosing these two instruments, the authors state that the two instruments have been 
concurrently validated previously by Ehde, Nitsch, & Smiley (2015). These authors found 
that while pain interfered with fatigue, depression and sleep in both women with MS and 
healthy controls, those with MS had significantly more chronic pain characterized by severe 
intensity and significant pain-related interference with activities. The second study is a 
secondary analysis that examines relationships among pain and demographic variables in 
women with MS, such that demographic factors other than sex could be explored (Newland et 
al., 2009). It also utilizes both the MPQ and BPI-long form. The authors explain that they 
used the MPQ to investigate pain prevalence while the BPI-long form examines interference 
and intensity. Women with MS with higher education levels were found to have lower 
prevalence, interference and intensity, than those less educated. Furthermore, employment 
was positively associated with decreased pain prevalence in the MS group. These findings 
suggest that less educated and unemployed women with MS are at increased risk to 
experience pain, according to the authors. 




Discussion. We found no evidence of reliability or validity testing of the BPI in 
NMOSD cohorts. The BPI addresses chronic pain in particular and includes items specific to 
pain severity as well as pain interference in a person’s life. Given the evidence to support that 
the quality of life in NMOSD patients is profoundly affected by pain, it seems advantageous 
to utilize a measure that recognizes and evaluates both of these aspects of pain. Like with 
cancer pain, being able to quickly and easily assess multidimensional features of pain is ideal 
in a population such as NMOSD because of the chronicity and severity of the pain that exists.  
In contrast to MS which predominantly affects Caucasians of northern European 
ancestry (Ontaneda, Hyland, & Cohen, 2012), NMOSD disproportionately affects non-
whites, particularly those of Asian and African descent (Mealy et al., 2012). Exploring 
validation of this measure in other languages with a high prevalence of NMOSD would be of 
value. NMOSD also disproportionately affects women at very high rates (6.5-9:1) (Mealy et 
al., 2012; Jarius et al., 2012). No testing particular to any one gender or sex was discovered 
during the literature review of the BPI. Research suggests that perception of and responses to 
pain differ by sex (Bernardes, Keogh & Lima, 2008; Rahim-Williams et al., 2012). This 
discrepancy is supported by Zhao’s findings in NMOSD, where 72% of women compared to 
27% of men reported pain (Zhao et al., 2014). Evaluating if responses differ by sex or 
whether the BPI is more sensitive in capturing pain in one sex versus the other would be of 
value. In conclusion, the BPI has excellent face validity for application in NMOSD and future 
research directed at establishing its reliability and validity in this population would prove 
useful.   
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Figure 4.  
MRI imaging showing C3-5 lesion following presentation of symptoms:  
A. T2-weighted sagittal 
B. T2-weighted axial 
C. T1-weighted sagittal post- gadolinium  
 




Figure 5.  
A. Electrode placement for Day 1 targeting the C6 distribution, and a second pair 
spanning over the C8 distribution.  
B. Due to decrease in the anatomic pain level, the electrode pairs were lowered to the 
dermatome that corresponded with C7 on Day 2. Two other electrode pairs were 
placed at C8-T1, and L5-L5. 
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Figure 6.  
NRS pain scores, daily pre- and post-treatment and at indicated follow-up intervals.  
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➢ In a multivariate model that included measurement of 
pain, fatigue, depression, and functional disability, 
only pain was a significant predictor of the overall 
QoL, when controlling for all other variables 
(p=0.0068). 
➢ Upon further exploration into the impacts on QoL, 
individual EQ5D items were examined, and high 
burdens were discovered among all five items; 
anxiety/depression (66.6% experienced at least some 
problems), pain/discomfort (75.0%), and mobility 










NMOSD and MS 
➢ Patients with NMOSD had more disability and pain 
than did patients with MS via t-tests. 
➢ Pain was the only symptom that was independently 
associated with all other symptoms via linear 
regression (p<0.05). 
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Neuromyelitis optica spectrum disorder (NMOSD) causes disabling and persistent central 
neuropathic pain (NP). Because the pain syndrome in NMOSD is severe and often intractable 
to analgesic treatment, it interferes with quality of life in patients. No interventional trials 
have been published looking at response to interventions for pain in NMOSD. This is a 
synthesis of the literature surveying the impact on quality of life of interventions in all 
mechanisms of central spinal NP. This review has important implications for management of 
pain in NMOSD. A systematic database search was conducted using Pubmed, Embase and 
CINAHL Plus with keywords including “spinal cord,” “quality of life” and “neuropathic 
pain” in an attempt to identify original research that targeted spinal NP treatment and used 
quality of life as an outcome measure. Both pharmacologic and non-pharmacologic 
treatments were sought out. Twenty-one studies meeting our eligibility criteria were 
identified and evaluated, 13 using pharmacologic treatments and 8 using non-pharmacologic 
interventions. Overall, sample sizes were modest, and effects on decreasing pain and/or 
improving quality of life were sub-optimal. This review provides researchers with a 
foundation from which to start a more thorough and thoughtful investigation into the 
management of NP in NMOSD and underscores the importance of including quality of life as 
a clinically meaningful outcome measure.  
 Keywords: neuromyelitis optica; neuropathic pain; quality of life, multiple sclerosis, 
spinal cord injury; chronic pain 
  




Review of treatment for central spinal neuropathic pain and its effect on quality of life: 
implications for neuromyelitis optica spectrum disorder 
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing autoimmune 
disorder of the central nervous system (CNS) that preferentially targets the spinal cord and 
optic nerves, leading to blindness, paralysis and death. NMOSD disproportionately affects 
non-Caucasians and females (Mealy, Wingerchuk, Greenberg & Levy, 2012; Jarius et al, 
2012), and has a worldwide prevalence estimated to be 0.52 to 4.4/100,000 (Marrie & Gryba, 
2013), affects approximately 4,000-8,000 people in the US, with a wide range of disease age 
at onset from infancy through old age (Mealy, et al., 2012; Jarius et al, 2012). In contrast to 
multiple sclerosis (MS) which primarily targets myelin, NMOSD causes irreparable neuronal 
cell death which leads to more severe disability and a poorer prognosis (Popescu & 
Lucchinetti, 2016). Historically, within five years of symptom onset, 60% of NMOSD 
patients were blind in at least one eye, 52% were weak in at least one limb requiring gait 
assistance and mortality was as high as 30% (Wingerchuk, Hogancamp, O'Brien & 
Weinshenker, 1999), though those data have improved with the identification of the highly 
specific AQP4 antibody (Wingerchuk, Lennon, Pittock, Lucchinetti & Weinshenker, 2006; 
Mealy et al., 2018).   
NMOSD causes severe, persistent pain which is more prevalent (83.8%-91%) than in 
MS (~47%) (Kanamori et al., 2011; Qian et al., 2012; Pellkofer et al., 2013) and most other 
neurological diseases (Borsook, 2012). The most common type of pain in NMOSD is central 
neuropathic pain (CNP), which is characterized as agonizing burning, shooting, tingling, 
lancinating, and squeezing sensations that are distressing, persistent and debilitating. Half of 
patients with NMOSD characterize their CNP as severe and two thirds report constant pain 




(Zhao, Mutch, Elsone, Nurmikko, & Jacob, 2014; Pellkofer et al., 2013). CNP typically 
presents weeks to months after the cord damage has occurred long after the acute injury, and 
may be a result of secondary changes due to reorganization of the damaged circuits of the 
somatosensory system (Sjolund, 2002). The pain can persist for years, decades or throughout 
the patient’s life. The presence and severity of pain in NMOSD may be influenced by lesion 
span and location: NMOSD lesions are generally transverse, involving both the central gray 
matter and dorsal horns. The dorsal horns are innervated by primary afferent fibers and 
contain a large number of excitatory (glutamatergic) and inhibitory (GABA (γ-aminobutyric 
acid)-ergic or glycinergic) interneurons, as well as projection neurons that convey sensory 
information to the brain (Todd, 2010; Bradl et al., 2014). Damage to the central gray matter in 
NMOSD leads to astrocytic damage and tissue necrosis, thus disrupting sensory pain tracts 
going to and from the brain (Qian et al., 2012; Kanamori et al., 2011). As a consequence of 
ongoing spontaneous activity arising in the periphery, surviving neurons develop increased 
background activity and increased responses to ascending nerve impulses, including normally 
harmless tactile stimulation (Centonze, 2014).   
Because many provider visits are dedicated to assessment and treatment of the 
underlying neurological disease, treatment of CNP is lacking despite increasing awareness of 
its impact on quality of life (QoL). Table 1 shows a comprehensive overview that includes 
seven studies assessing pain and QoL in NMOSD to date, none of which focus on an 
intervention or treatment. However, three studies have found promising results when 
examining pain as a secondary outcome, two in patients receiving a humanized monoclonal 
antibody that targets interleukin(IL)-6 for disease suppression, (Araki et al., 2014; Ringelstein 




et al., 2015) and one in patients receiving low-dose mycophenolate mofetil (Huang et al., 
2018), though none of these studies investigated QoL outcomes.   
Research on the impact of persistent pain on QoL in NMOSD has found that those 
patients with CNP experience more depression, less enjoyment of life, and more difficulty 
with ambulation (Mutch et al., 2014; Pellkofer et al., 2013; Zhao et al., 2014). CNP is 
particularly resistant to most currently available treatments (Qian et al., 2012; Zhao et al., 
2014). The most common medication classes for the treatment of CNP, used off-label, are 
anti-epileptics, anti-depressants and non-steroidal anti-inflammatories, but many patients still 
require frequent opioid use (Qian et al., 2012; Zhao et al., 2014). Cannabinoids have been 
recently considered for CNP as they become more available for use, though no data specific 
to this population have been analyzed. Despite this analgesic armament, NMOSD patients 
continue to have pain, in contrast to nearly half of MS patients treated for their CNP who 
report being pain-free (Qian et al., 2012).  
Another factor to consider is that the medications used for treatment of CNP have side 
effects, particularly at higher doses, and are independently associated with slower reaction 
times and fatigue (Qian et al., 2012). Acknowledging that randomized control trials have 
demonstrated efficacy of non-pharmacologic interventions for other pain conditions, 
researchers have sought to extend this work to SCI and MS populations for the treatment of 
CNP, with interventions such as nerve stimulation, acupuncture, exercise and massage 
therapy (Widerstrom-Noga and Turk, 2003; Boldt et al., 2014; Namjooyan et al., 2014). 
These studies are limited by small sample size and the potential bias of symptom self-report, 
and they often include therapies not generally covered by insurance. 




Despite research of both pharmacologic and non-pharmacologic interventions in CNP, 
as well as research suggesting that CNP impacts QoL, few studies have specifically examined 
whether a given intervention that targets pain has any side benefit on QoL. This review 
sought to extract, evaluate, and synthesize the literature regarding the impact of CNP 
interventions on QoL. This review is subdivided by pharmacologic and non-pharmacologic 
interventions. As no such literature exists specifically in NMOSD, central spinal pain was 
sought out broadly and included related conditions including MS and spinal cord injury of 
multiple etiologies.    
Methods 
A research review was conducted by performing database searches of Pubmed, 
Embase, and CINAHL Plus. Search terms included “neuropathic pain” and “quality of life” 
for each search, and the terms “spinal cord,” “myelitis” and “multiple sclerosis” were each 
independently added to these terms in an effort to capture a comprehensive look at all causes 
for central NP of the spinal cord; this generated 975 citations (202 Pubmed, 721 Embase, 52 
CINAHL). Results were further limited to articles and book chapters, human subjects, 
English language, by adding to the search “treatment” OR “intervention” OR “therapy” and 
by searching for “pain” specifically in article titles, which narrowed the search to 326 (114 
Pubmed, 192 Embase, 20 CINAHL). Articles were not limited by date. Literature reviews 
that were not systematic, publications that were not peer-reviewed, and descriptive case 
reports were excluded. Duplicate articles were removed. Treatments directed to non-spinal 
cord etiologies or those that did not differentiate among location (spinal cord vs. supraspinal 
vs. peripheral) and/or types (neuropathic versus nociceptive) of pain were also excluded, and 
clinical judgment was exercised when interpretable based on description and location of the 




pain, in an effort to be inclusive when appropriate. Articles were included only if QoL was 
considered as an outcome (primary or secondary) following an intervention for CNP 
treatment, leaving 153 abstracts/articles for analysis in this review.  
Results 
Twenty-one interventional studies met inclusion criteria and were reviewed (see 
Figure 1). Across all studies, 910 patients were analyzed (438 SCI, 290 MS, 182 other). There 
were no studies focused on patients with NMOSD. 
Sex was described in all but one study (n=24). Of the remaining aggregate sample of 
886, 53% of participants were female. Demographic characteristics of race/ethnicity were 
described only in the three U.S. studies (aggregate n=263). Among these, 236 were 
White/Caucasian descent (90%), 22 were Black/African descent (8%), three were 
Hispanic/Latino descent (1%), one was Native American and one was classified as “other.” 
Effect of Pharmacologic Interventions on QoL 
Thirteen studies examined the effect of a pharmacologic intervention or treatment on 
QoL as a primary or secondary outcome (Table 2). Five studies evaluated the benefit of anti-
epileptic medications (AEDs) for first-line treatment for CNP (Finnerup et al., 2015) in MS (2 
studies), SCI (2 studies) and one was in a heterogeneous group of patients with CNP, a subset 
of whom had an undifferentiated spinal etiology. The rationale for using this class of 
medication for treatment of CNP was similar to the rationale for use in seizures: the drugs 
decrease hyperexcitability in damaged areas of the CNS caused by a sustained depolarization 
and inhibit voltage-dependent sodium channels, reducing the capacity of neurons to generate 
high-frequency action potentials (Salinas et al., 2012). A randomized, double-blind, placebo-




controlled clinical trial using early AED intervention with carbamazepine to prevent the onset 
of CNP in SCI did not show a significant difference between the intervention and control 
groups (Salinas et al., 2012) suggesting that preemptive analgesia does not prevent the 
subsequent onset of CNP. The other four studies were conducted using patients after CNP 
onset, three of which found that reducing pain positively impacted QoL. Gabapentin, 
pregabalin and levetiracetam reduced pain by 50-100% on average and improved self-
reported Visual Acuity Scale ratings through the course of treatment (Levendoglu, Ogun, 
Ozerbil, Ogun & Ugurlu, 2004; Vranken et al., 2008; Rossi et al., 2009) (Table 2). Overall, 
these findings support that use of AEDs for CNP treatment and improvement of QoL.  
Two RCTs studied the effects of the serotonin noradrenaline reuptake inhibitor 
(SNRI) duloxetine use on pain (Vranken et al., 2011; Vollmer, Robinson, Risser & Malcolm, 
2014), although SNRIs are not as commonly used for pain worldwide compared to tricyclic 
anti-depressants (Finnerup et al., 2015). The stated rationale for using duloxetine was to 
inhibit the reuptake of serotonin and noradrenaline to potentiate monoamine 
neurotransmission in the descending inhibitory spinal pathways. This results in reduced 
nociceptive afferent transmission in the ascending spinal pain pathways to decrease the 
sensation of pain. Potentiation of both serotonin and noradrenaline is required to produce 
effective analgesia (Lunn, Hughes & Wiffen, 2014). The smaller of these studies (n=40) 
examined the effects of duloxetine in SCI-induced pain showed improvements in QoL 
including in the area of pain, but no improvement in independent pain scales (Vranken et al., 
2011). In the larger study (n=239) duloxetine in MS patients with CNP resulted in significant 
reductions in pain throughout the end of the extension phase, without effecting any change in 
QoL (Vollmer et al, 2014). These seemingly conflicting results may be because the studies 




used different survey tools, highlighting the importance of using standardized, validated 
measures of pain and quality of life.   
Cannabinoid agents were investigated in two small RCTs, both in MS (Svendsen et 
al., 2004; Turcotte et al., 2015). Cannabinoids are ligands that bind on the presynaptic 
cannabinoid receptor, resulting in reduced calcium influx from voltage-gated calcium 
channels and hyperpolarization, thus decreasing cellular excitability (Turcotte et al., 2015). 
Both of the cannabinoid agents used in these studies uncovered a significant impact on pain 
with the larger of the two additionally impacting QoL. The smaller, more recent study 
evaluated the use of nabilone, a synthetic tetrahydrocannabinol, in patients who were already 
on stable doses of gabapentin (Turcotte et al., 2015). As used this study, multimodal 
approaches to CNP treatment that target dual mechanisms of CNP treatment may be more 
effective at improving both pain and QoL.  
Two opioids were assessed for treatment of CNP: tramadol and oxycodone. Opioids 
bind to an opioid receptor, causing inhibition of adenylyl-cyclase and hyperpolarization of 
neurons, and decreased excitability (Ordonez Gallego, Gonzalez Baron & Espinosa Arranz, 
2007). One of the medications, tramadol, has a second mechanism of action similar to SNRIs, 
as described above (Norrbrink and Lundeberg, 2009). Both studies showed improvement in 
pain, though a limitation of the oxycodone study (Ordonez Gallego et al., 2007) is that it was 
an observational study and oxycodone dosing was not standardized by the study protocol. 
Another study examined the effect of botulinum toxin type A (BTX-A) for CNP 
treatment in patients with SCI (n=40). The mechanism of action proposed in CNP is based on 
its mechanism in nociceptive pain, which suggests that BTX-A may inhibit neurogenic 




inflammation and the peripheral sensitization of nerve fibers by inhibiting the release of local 
neuropeptides, thereby reducing pain. The study reported a significant reduction in pain, 
though only a marginal trend toward significance on QoL. 
Intravenous immunoglobulin (IVIG) contains the pooled polyvalent IgG antibodies 
extracted from the plasma of thousands of blood donors and is generally used to decrease 
inflammation. The exact mechanism of action has not been well-elucidated, but it is theorized 
that a high load of exogenous antibodies leads to a robust antibody recycling process that 
turns over both exogenous and endogenous antibodies (Sapir & Shoenfeld, 2005). This 
therapy was examined in post-polio syndrome (n=142; 75 with CNP): polio causes acute 
inflammation of the spinal cord leading to weakness, fatigue and pain persisting long after the 
acute infection has resolved (Gonzalez et al., 2006). Ongoing denervation has been suggested 
to be the most important reason for progressive muscle weakness associated with 
poliomyelitis infection. Patients with post-polio syndrome have increased expression of 
messenger RNA for proinflammatory cytokines in cerebrospinal fluid, which may suggest an 
ongoing inflammatory process in the CNS (Gonzalez et al., 2006). As such, the researchers 
hypothesized that targeting inflammation with IVIG may improve weakness or stop its 
progression. Pain was a secondary study outcome, but notably it was reduced in this patient 
population. QoL was not significantly impacted. 
Effect of Non-pharmacologic Interventions on QoL 
Eight studies were identified that examined the effect of a non-pharmacologic 
intervention for CNP on QoL. Non-pharmacologic interventions included the use of physical 
therapy (PT) and exercise, transcutaneous electrical nerve stimulation (TENS), cognitive 




behavioral therapy (CBT) and complementary and alternative medicine (CAM) approaches 
(Table 3). 
In rats, regular moderate aerobic exercise reversed signs of CNP and increased 
endogenous opioid content in brainstem regions important in pain modulation (Stagg et al., 
2011). This approach was translated to a small human study in SCI that showed significant 
improvements in both QoL and pain, suggesting that a larger study with PT and exercise is 
warranted (Norrbrink, Lindberg, Wahman, & Bjerkefors, 2012). Transcutaneous electrical 
nerve stimulation (TENS) uses electric current to stimulate denervated nerves through 
electrodes placed on the skin (Norrbrink, 2009). Effectiveness has been shown for use in 
peripheral neuropathy, but results in the treatment of central NP have been equivocal. Sites in 
the spinal cord and brainstem that utilize opioid, serotonin, and muscarinic receptors have 
been shown to be activated by peripheral nerve stimulation by TENS, but lack of standards on 
ideal frequency and stimulation amplitude needed to achieve pain reduction has hampered the 
use of TENS in clinical trials of CNP (Norrbrink, 2009; Sluka et al., 2013).  
Psychological factors are believed to influence the maintenance and aggravation of 
CNP, suggesting that psychological interventions with traditional biomedical interventions 
may reduce the burden of CNP (Heutink et al., 2014). Four studies evaluated the 
effectiveness of Cognitive Behavioral Therapy (CBT) for CNP treatment, all in SCI 
(Norrbrink Budh, Kowalski, & Lundeberg, 2006; Nicholson Perry et al., 2009; Heutink et al., 
2012; Heutink et al., 2014). CBT focuses on modifying an individual’s beliefs, expectations 
and coping abilities (Norrbrink Budh et al., 2006). One study reduced pain without improving 
QoL, two studies improved QoL only, and one had no impact on pain or QoL. CBT is aimed 
at modifying a patient’s response to pain rather than directed at the pain itself, explaining the 




finding that three of the studies did not impact pain significantly. Interestingly, all four 
studies had some impact on anxiety and/or depression, adding strength to the argument that 
this intervention improves pain responses rather than the physical experience of pain itself. 
Complementary and Alternative Medicine (CAM) refers to treatments that are outside 
of conventional medicine which have for the most part not been rigorously tested and often 
evolve from traditional Asian medicine. The American public's use of CAM therapeutic 
modalities has grown exponentially in recent years, including for CNP (Namjooyan et al., 
2014). This may be a product of the fact that CNP is often not affected in a clinically 
meaningful way, leading patients to look for other options. Common examples of these are 
acupuncture and massage therapy. Acupuncture is the stimulation of specific points through 
which the life-energy flows along the skin of the body using thin needles, in an attempt to 
achieve balance. Healing Touch (HT) similarly aims to achieve balance in life-energy 
through touch. Progressive muscle relaxation (PMR) is a technique focused on controlling the 
state of muscular tension and involves learning to monitor tension in each specific muscle 
group in the body by deliberately inducing and releasing tension in each group. The study 
examining HT versus PMR was the only mixed methods study reviewed; no significant 
impact was found on pain and QoL differences favoring HT were captured in the qualitative 
component alone (Wardell, Rintala, Duan, & Tan, 2006). In the study investigating the effects 
of acupuncture versus massage therapy, no differences in amount of pain were found but the 
data suggest that acupuncture may have prevented worsening of pain compared to therapeutic 
massage (Norrbrink and Lundeberg, 2011). 
The concept of integrative medicine combines evidence-based treatments with 
alternative and non-pharmacologic options, in an attempt to approach treatment in a more 




holistic manner, and may be a promising next step in this arena. There are no trials or studies 
that systematically used a combination of pharmacologic and non-pharmacologic treatments 
for central spinal CNP using QoL as an outcome measure. 
Discussion 
This is a comprehensive literature review examining the state of the science in spinal 
CNP treatment utilizing QoL as a primary or secondary measure. Hundreds of articles were 
found that examined the impact of a given intervention on CNP or the impact of CNP on 
QoL, but only these 21 could be identified that included an examination of the impact of a 
pain intervention on QoL. However, impacting pain alone may not be clinically meaningful 
to a patient if QoL is not also enhanced. Given that pain affects QoL (Newland et al., 2009; 
Kanamori, 2011), it seems reasonable that an objective of pain treatment should be aimed at 
improving QoL in patients as well. It is striking that so few studies have applied QoL 
measures as an outcome. In order to meet patient-centered goals of improving QoL, future 
studies should include measures of both pain and QoL.  
Also notable is the seeming mismatch between reported effects on pain levels and 
QoL, such that improvement in pain did not necessarily translate to improvement in QoL: of 
the 21 studies examined, 6 were shown to positively impact both pain and QoL, 4 failed to 
impact either, 7 impacted pain only and 4 impacted QoL only. There are several possible 
explanations as to why half of the studies had a mismatch between effects on pain and effects 
on QoL. First, many of the studies were relatively small, with a median sample size of 29.5 
(range 8-239). Thus, some studies may have been adequately powered to address the primary 
outcome, but not sufficiently powered to identify significant differences in secondary 




outcomes, including QoL. Second, there was a wide array of both pain measures and QoL 
measures used, and while most have been validated in some populations, not all have been 
validated specifically in the populations that were investigated; see reviews of instruments for 
SCI, MS, and NP (Breivik et al., 2008; Stadhouder et al., 2010; Kuspinar and Mayo, 2014). 
Using validated measurement tools, or combining tools may draw out significant findings.   
Another possible explanation for the mismatch between treatment of NP and its effect 
on QoL could be explained by recent research on symptom clusters. Symptom clusters consist 
of two or more related symptoms that co-occur and that may or may or may not share a 
common etiology (Kim, Abraham, & Malone, 2013). In chronic disorders, patients often 
present with multiple inter-related symptoms, which may explain why treating one symptom 
does not necessarily impact quality of life. While much of the research in symptom clusters 
has focused on cancer, the concept is applicable to a wide array of chronic conditions, 
including NMOSD, MS and SCI. The implication for NMOSD is that treating CNP in 
isolation may not impact QoL in a disease that causes other debilitating symptoms, including 
anxiety, depression, fatigue, sleep dysfunction and bladder dysfunction (Pan et al., 2015; 
Mutch et al., 2015; Hollinger et al., 2016; Shi et al., 2016; Mealy, Boscoe, Caro & Levy, M. 
2018). 
There was relative balance in the number of females to males represented overall 
(54%). SCI made up 39% of the total number of participants among trials, which has a high 
male-to-female ratio of 2.6-7:1 internationally (Singh, Tetreault, Kalsi-Ryan, Nouri & 
Fehlings, 2014). Counterbalancing this were the MS patients (42% of the total sample) where 
the female-to-male ratio is 2-3:1 (Koch-Henriksen & Sørensen, 2010).  Only three studies 
reported on race/ethnicity, and all of these were from the United States and all predominantly 




white. Although many of the countries represented are fairly homogenous groups, 
demographics continue to change worldwide and it is problematic to fail to report on social 
determinants of health and inequities between groups, especially among groups where health 
inequities are known to be present and where perceptions of pain differ (Bernardes, Keogh & 
Lima, 2008; Rahim-Williams et al., 2012). Some research suggests that biopsychosocial 
mechanisms may underlie these differences (Paller, Campbell, Edwards, & Dobs, 2009). Of 
interest would be a comparison of responses to non-pharmacologic interventions, and 
particularly to CBT which is guided by the biopsychosocial model (Nicholson Perry et al., 
2009; Heutink et al., 2012; Heutink et al., 2014).  
Conclusion 
NMOSD causes damage to CNS pathways in the spinal cord as occurs in MS and SCI, 
suggesting that it is reasonable to extrapolate data from MS and SCI to guide therapy in 
NMOSD while also recognizing that different outcomes may result in part due to disparities 
in sex and race in NMOSD. CNP is difficult to treat and is pervasive in NMOSD. Treatments 
are ineffective and individual pain interventions are not sufficient to impact QoL. These 
factors only further underscore the need for broadening treatment options and using a 
multimodal approach in this population. It is important to focus attention on what symptoms 
form clusters and on comprehensive treatment regimens that address these clusters. A 
practical and potentially clinically meaningful trial for future research may examine a 
combination of an AED, anti-depressant, CBT and exercise program. This may highlight how 
the cluster of symptoms is impacted differently between the two groups, with emphasis on 
how this translates to improved quality of life.  
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Inclusion criteria: search of 
databases for "neuropathic 
pain" AND "quality of life" 
PLUS "spinal cord" OR 

















Search terms “pain” added to TITLE and “treatment” 
OR “intervention” OR “therapy” added. Limited to 
articles and book chapters, human subjects, English 
language 
Duplicates, reviews and 
non-peer reviewed 
articles excluded  
Reviewed for content: quality of life as outcome measure 
following intervention or treatment included; case studies 
excluded, non-spinal cord pain, or no differentiation of 
pain by location or type excluded. 
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37 NMOSD patients (35 
AQP4+; 36 female); 51 
MS patients as 
comparator (37 female) 
Descriptive 
comparative 
BPI SF-36 This was the first study that explored pain in NMO. 
Pain in NMOSD (83.8%) was more common than in 
MS (47.1%), and also more severe. QoL was also 
significantly poorer in the NMOSD group in the areas 
of bodily pain, physical functioning and general 
health. Consecutive sampling was used for participant 
recruitment. While this study did not investigate or 
account for medication use and was limited in the 
number of variables assessed, this pivotal study shed 
light on the issue of pain in NMO. 
 
Qian et al. 
(2012);  
US 
29 NMOSD patients (24 
AQP4+; 24 female; 14 
White/Caucasian, 14 
Black/African descent, 1 
Asian descent); 66 MS 
patients as comparator 








SF-36 This study assessed pain and other symptoms, 
neurological function, spinal cord damage, and QoL. 
Pain in NMOSD (86.2%) was more common than in 
MS (40.9%), and also more severe, even after 
controlling for disability and spinal cord damage. Pain 
correlated with worse physical and mental scores on 
SF-36.  
This was the first study to examine medication use: 
prescription pain medications were used significantly 
more frequently in NMOSD participants, more often 
required multiple medications and all treated patients 
experienced pain despite treatment.  
 
Pellkofer et 
al. (2013);  
Germany 
11 NMOSD patients (11 




SF-36 This study aimed to investigate presence and clinical 
characteristics of pain, stress and depression, and 
evaluated endocannabinoid levels and abnormalities in 
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somatosensory functioning. Recruitment was through 
consecutive sampling. 91% endorsed NP within 
previous 3 months and 72% reported ongoing NP; 
decreased QoL in 3 of 8 measures: physical 
functioning, general health and bodily pain. This study 
also aimed to explore the role of endogenous 
cannabinoids and found plasma levels of 2-AG to be 
significantly higher in NMOSD patients, suggesting 
that central sensitization is controlled by it. 
 
Zhao et al. 
(2014);  
UK 
50 NMOSD patients (41 
AQP4+; 39 female; no 
race/ethnicity data made 
available) 
Descriptive BPI SF-36  This study specifically explored NP more in-depth. 
Patients were assessed for pain and QoL through use 
of structured interviews and measurement tools, and a 
retrospective record review was conducted to examine 
MRI data, medication use and neurologic functioning.  
62% of patients experienced NP, with 68% of those 
having constant pain affecting ADLs. Interestingly, 
72% of females versus 27% of males reported pain. 
25% of patients reported pain as their worst symptom, 
despite mobility and/or vision issues. Physical 
component of QoL was equally low in those patients 
with and without pain, specifically in the areas of 
physical functioning, general health and bodily pain. 
Mental component was significantly lower in those 
with pain. 
 
Mutch et al. 
(2014);  
UK 
15 NMOSD patients (9 
AQP4+; 11 female; no 










First qualitative study to explore QoL, including pain. 
Poor vision, reduced mobility, bladder dysfunction 
and pain affected participants’ independence and 
experience of living with NMO. Expressed anxiety 
regarding unpredictability of disease and desire for 
normalcy. 
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Patients reported anxiety and low mood, particularly 
following diagnosis and after relapses. Twelve 
patients reported pain, and indicated that it 
considerably affected their daily activities, mood, 





49 NMOSD patients (29 
AQP4+, 14 MOG+; 41 
female; no race/ethnicity 
data made available) 
Descriptive  painDETECT  SF-36 Eighty-six percent of patients reported pain, regardless 
of antibody status. Pain correlated with QoL, but 
treatment of pain was not effective at improving QoL.  




522 NMOSD patients 
(self-reported; AQP4 
status unknown; 283 
female; race data 




15 Asian; 6 other) 
Descriptive Self-report PLM 
quality of 
life survey 
This study reports the patient perspective of those 
with NMOSD via an online community called 
PatientsLikeMe and found that 53% of NMOSD 
patients report moderate to severe pain. Fifty-nine 
percent reported that their health limited their work 
and activities all or most of the time. Physical and 
emotional health interfered with social activities.  
*values were considered significant at p<0.05, unless otherwise noted 
NMOSD=neuromyelitis optica spectrum disorder; MS=multiple sclerosis; NP=neuropathic pain; BPI=Brief Pain Inventory; SF-36=Short Form 36 health survey; 
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et al. (2004); 
Turkey 
SCI patients c/ NP; 
n=20 (7 female; no race 









Significant decrease in intensity and frequency 
of most descriptors of pain (sharp, hot, 
unpleasant, deep, and surface) and disability 
and sleep were significantly better in the GBP 
treatment group. This was the 1st RCT to 
include QoL measures, in one of the most 
commonly used medications for NP treatment, 
however another measure of QoL would be 
helpful to capture a fuller picture of effects on 
health status.  
 
Breuer et al. 
(2007);  
US 
MS patients c/ spinal NP;  











Pilot study showed no significant difference in 
pain or QoL; did not support need for larger 
trial. 
Vranken et 
al. (2008);  
Netherlands 
Patients c/ NP; subset was 
spinal;  
n=40 (19 female; 20 in 
treatment group; no race 
data made available); 21 
patients with spinal cause  
RCT Pregabalin in 
addition to 
stable regimen, 





There was significant decrease in mean pain 
score for pregabalin treatment group, compared 
with placebo. No difference in PDI between 
groups but treatment group showed significant 
improvement for the EQ-5D utility score and 
EQ-5D VAS score compared with the placebo 
group and SF-36 indicated that treatment led to 
a significant improvement in the bodily pain 
domain only. 
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Rossi et al. 
(2009);  
Italy 
MS patients c/ spinal NP; 
n=20 (15 female; 12 in 
treatment group; no race 





Significant reduction in pain for treatment 
group; no difference in reported QoL, except 
for the item, ‘overall rating of quality of life.’ 
Salinas et al. 
(2012);  
Colombia 
SCI patients s/ NP;  
n=46 (4 female; 24 in 
treatment group; no race 




titrated up to 
600 mg/day 
SF-36 This novel study looked at prevention of NP 
with early treatment, rather than treatment in 
those who already experience it. Early 
intervention did not decrease incidence of NP 
over time and there was no difference in QoL 






SCI and stroke patients c/ 
NP;  
n=48 (24 in treatment 
group; Table 1, 












No difference in pain intensity with treatment. 
Treatment group showed a significant 
improvement for the bodily pain domain only 
of the SF-36. No significant differences were 
observed in other QoL indices. The distribution 
of spinal versus supraspinal NP is said to be in 
Table 1 (Demographics), but no such table was 
included in the manuscript and spinal NP could 
not be separately assessed. 
 
Vollmer et al. 
(2013); 
US 
MS patients c/ spinal NP;  
n=239 (189 female; 221 
white, 15 African descent, 2 
Hispanic, 1 Native 
American; 118 in treatment 
group); 209 in OLE 
Multi-center 





titrated up to 60 
mg/day in RCT 
and up to 120 
mg/day in OLE 
MSQoL-
54 
This well-conceived, well-executed, 
international study showed significant pain 
reduction in treatment group; QoL was not 
impacted. In OLE, pain reduction was reported 
in patients in both groups, with greater 
improvement reported by patients who had 
received placebo during the acute phase. 
Cannabinoids 
Svendsen et 
al. (2004);  
Denmark 
MS patients c/ spinal NP; 
n=24 (14 female; no race 




titrated up to 10 
mg 
SF-36 Pain intensity and reduction significantly 
improved on treatment; the only improvements 
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MS patients c/ NP 
refractory to GPB; n=15 
(13 female; 8 in treatment 
group; no race data made 
available) 
RCT Nabilone, 
titrated up to 1 
mg, in addition 
to stable GBP 
dose 
VASimpact This small but well-designed study explores 
the important need for combining medication 
therapies, and shows that combination of GBP 
with nabilone significantly reduces pain. No 
change in pain impact was noted, however, the 
use of a VAS to capture impact of pain may 
have been inadequate and a more 








SCI patients c/ NP;  
n=35 (7 female; 23 in 
treatment group; no race 






titrated up to 
400 mg/day  
LiSat-9 Decrease in pain intensity in treatment group 
compared with those on placebo. Global life 
satisfaction improved in placebo group only. 
Barrera-
Chacon et al. 
(2011);  
Spain 
SCI patients c/ NP 
refractory to AED 
treatment;  
n=54 (10 female; no race 










Significant decrease in pain intensity, 
improved health-related QoL and diminished 
impact of pain on physical activity and sleep. 
As doses of oxycodone were not investigated, 
further research in controlled trials assessing 




Han et al. 
(2016); 
Korea 
SCI patients c/ NP; n=40 
(14 female; 20 in treatment 











The BTX‐A group showed significant 
reductions in pain score at 4 and 8 weeks 
following injection, compared to placebo. 
Trend towards significant impact in physical 
health domain of QoL only. 




al. (2006);  
Sweden 
Post-polio syndrome 
patients; subset had NP;  
n=142; 75 patients with NP 
(33 of whom are in 
treatment group; 92 females 
in total group, not 
differentiated by pain 
status; no race data made 
available) 
 
RCT IVIG, 90 g over 
3 days c/ 2nd 
equal dose at 3 
months 
SF-36 Pain assessment was a secondary end-point of 
this study that primarily assessed strength, and 
not all patients included had NP. In the 
subcohort of patients with significant pain, 
those receiving IVIG had a greater pain 
reduction. QoL did not differ between groups. 
*values were considered significant at p<0.05, unless otherwise noted 
SCI=spinal cord injury; MS=multiple sclerosis; NP=neuropathic pain; RCT=Randomized Controlled Trial; GBP=gabapentin; MSQoL=Multiple Sclerosis Quality of Life 
instrument; EQ-5D=EuroQoL-5 Dimensions instrument; VAS=Visual Analog Scale; WHOQOL-BREF=World Health Organization Quality of Life-abbreviated; PDI=Pain 
Disability Index; SF-36=Short Form 36 health survey; OLE=open-label extension; BTX-A= botulinum toxin type A; IVIG= Intravenous immunoglobulin 
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Patient Sample Study Design 
 
Intervention QoL Measure Findings & Comments 
 




SCI patients c/ NP;  
n=24 (4 female; no 







LiSat-9 In this study with high attrition and difficulty 
with enrollment, pain intensity was unchanged 
compared with baseline values on a group level 
and no differences were found between the two 
modes of stimulation, and no effect on 
secondary measures including life satisfaction 
was noted.  
 
Norrbrink et 
al. (2012);  
Sweden 
SCI patients c/ 
musculoskeletal 
and/or NP;  
n=8; 7 patients with 
NP pain (1 of whom 
is female; no race 






SCI QoL data 
set 
Descriptive statistics were utilized alone since 
inferences could not be made in this small 
cohort. For those with neuropathic pain, median 
pain intensity ratings decreased from 5 on a 0–
10 numerical rating scale at baseline to 3 at the 
end of study. All median ratings of QoL showed 
improvement. Results in this exploratory study 
are promising and need to be further explored in 
a larger controlled study. 
 
Cognitive Behavioral Therapy Programs 
Norrbrink 
Budh et al. 
(2006); 
Sweden 
SCI patients c/ NP;  
n=38 (24 female; 27 
in treatment group; 





CBT NHP In this non-randomized study, no difference 
from baseline in pain or QoL was found in 
treatment group, or between groups. 
Improvement in sleep quality and mood 
detected in treatment group, not affecting 
composite score.  
 




Perry et al. 
(2009);  
Australia 
SCI in patients c/ 
NP; n=36 (8 female; 
19 in treatment 









No changes in pain intensity between or within 
groups over time, though there was significant 
improvement in pain-catastrophizing for the 
treatment group. QoL improved for mental but 
not physical status.  
Heutink et al. 
(2012); 
Netherlands 
SCI patients c/ NP;  
n=61 (22 female; 31 
in treatment group; 




CBT LiSat-9 In the first RCT of CBT, short-term decrease in 
pain was detected, but this was not sustained at 
3-month follow-up. No change in life 
satisfaction was identified, but anxiety and 
depression decreased in the intervention group. 
 
Heutink et al. 
(2014);  
Netherlands 
SCI patients c/ NP;  
n=29 (9 female; no 







CBT LiSat-9 Pain intensity was significantly decreased at 12-
month follow-up; no changes in life satisfaction 
or depression over time, though significant 
decrease in anxiety was noted. 
Complementary and Alternative Medicine  
Wardell et al. 
(2006);  
US 
SCI patients c/ NP; 
n=12 (0 female; 4 
white, 3 African 
descent, 1 Hispanic, 


















This small pilot study of all-male veterans did 
not reveal significant changes in pain or life 
satisfaction. However, the HT group had 
variable responses and the qualitative 
component indicated that a subset of patients 
experienced benefit suggesting that while this 
pilot study was not powered appropriately to 






SCI patients c/ NP;  
n=30 (6 female; 15 
in treatment group; 









LiSat-9 This small exploratory study found a significant 
difference between the two groups at end of 
treatment in favor of acupuncture, but no 
within-group differences in pain at follow-up. 
No impact on life satisfaction. 
 
 *values were considered significant at p<0.05, unless otherwise noted 
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SCI=spinal cord injury; MS=multiple sclerosis; NP=neuropathic pain; RCT=Randomized Controlled Trial; GBP=gabapentin; SCI QoL=Spinal Cord Injury Quality of Life 
instrument; EQ-5D=EuroQoL-5 Dimensions instrument; HT=Healing Touch; SWLS=Satisfaction with Life Scale; LiSat-9=Life Satisfaction-9; CBT=Cognitive Behavioral 
Therapy: NHP=Nottingham Health Profile extension  
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in patients with neuromyelitis optica spectrum disorder: a phase II randomized controlled trial 
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The primary objective aimed to determine if Scrambler therapy is an effective, acceptable and 
feasible treatment of persistent central neuropathic pain in patients with neuromyelitis optica 
spectrum disorder (NMOSD). The secondary objective explored the effect of Scrambler therapy 
on co-occurring symptoms. We conducted a randomized single blind, sham-controlled trial in 
patients with NMOSD who have central neuropathic pain using Scrambler therapy for 10 
consecutive weekdays. Pain severity, pain interference, anxiety, depression and sleep disturbance 
were assessed at baseline, end of treatment, and at 30- and 60-day follow-up. Twenty-two 
patients (11 per arm) were enrolled into and completed this trial. The median baseline NRS pain 
score decreased from 5.0 to 1.5 following 10 days of treatment with Scrambler therapy, whereas 
the median NRS score did not significantly decrease in the sham arm. Depression was also 
reduced in the treatment arm, and anxiety was decreased in a subset of patients who responded to 
treatment. These symptoms were not impacted in the sham arm. The safety profiles were similar 
between groups. Scrambler therapy is an effective, feasible and safe intervention for central 
neuropathic pain in patients with NMOSD. Decreasing pain with Scrambler therapy may 
additionally improve depression and anxiety. 
Clinicaltrials.gov identifier 
NCT03452176 
Classification of Evidence 
This study provides Class 1 evidence of Scrambler therapy use in patients diagnosed with 
NMOSD who have central neuropathic pain. 
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Scrambler therapy is a safe and feasible intervention that improves neuropathic pain in patients 
with neuromyelitis optica spectrum disorder: a phase II randomized controlled trial 
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the 
central nervous system that causes recurrent inflammatory attacks of the optic nerves and spinal 
cord, leading to blindness, paralysis and death (Oh & Levy, 2012). Despite these devastating 
consequences of the disease, patients have reported that pain is among the most prevalent and 
debilitating symptom which impacts mood, mobility and quality of life (QoL) (Qian et al., 2012; 
Zhao et al., 2014; Kanamori et al., 2011; Hollinger et al., 2016; Shi et al., 2016; Moore et al., 
2016; Kong et al., 2016). In particular, central neuropathic pain is pervasive, severe, intractable 
to treatment, and affects 62-91% of patients with NMOSD (Zhao et al., 2014; Pellkofer et al, 
2013). Currently, there is no standard of care for central neuropathic pain treatment, and the most 
frequently-used medications for its treatment in NMOSD are anti-epileptics, antidepressants and 
non-steroidal anti-inflammatory agents. Descriptive studies in NMOSD acknowledge the 
inadequate effect of these medications, and effective treatment for central neuropathic pain in 
NMOSD is still lacking (Qian et al., 2012; Zhao et al., 2014). 
Scrambler therapy is a new, non-invasive technology with Food and Drug Administration 
(FDA) 510(k) approval, "Scrambler ST 5 TENS Device," (K081255) granted in February 2009 
for acute, chronic and post-operative pain (FDA, 2019). Scrambler is a type of transcutaneous 
electrical nerve stimulation (TENS) that uses peripheral nerve stimulation of ascending C fibers 
to modify nociceptive responses with the intent of re-organizing maladaptive signaling pathways 
in the sensory cortex (Majithia et al., 2016). This neuromodulatory therapy has been investigated 
for treatment of persistent peripheral neuropathic pain, largely in open-label observational trials, 
in several conditions including chemotherapy-induced neuropathy, post-herpetic neuralgia and 
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post-surgical neuropathic pain with promising results (Majithia et al., 2016; Smith et al., 2017; 
Joo et al., 2017; Park et al., 2017; Kim et al., 2017; Kashyap et al., 2017; Smith et al., 2017). 
Patients report sustained relief after undergoing daily treatment sessions for 10 consecutive 
weekdays (Majithia et al., 2016).  
There is anecdotal evidence supporting Scrambler therapy for use in patients with 
persistent central neuropathic pain (D’Amato et al., 2018; Mealy et al., in press), but there are no 
rigorous studies that systematically tested the benefit or sustainability of Scrambler versus a 
placebo treatment. The aim of the current study investigates use of Scrambler for treatment of 
central neuropathic pain in patients with NMOSD, given the substantial unmet need and lack of 
investigation into pharmacologic or non-pharmacologic intervention for pain management in this 
patient population.  
Methods 
We conducted a randomized single blind, sham-controlled trial in patients with NMOSD 
who have central neuropathic pain using Scrambler therapy. The central hypothesis that guided 
this study was that Scrambler therapy is an acceptable and feasible treatment that significantly 
reduces pain and improves co-occurring symptoms in patients with NMOSD.   
Standard protocol approvals, registrations, and patient consents 
We enrolled 22 patients with NMOSD (11 per arm) at the Johns Hopkins Neuromyelitis 
Optica Clinic. Participants with severe limitations to mobility or sight due to their disease were 
given the option to have study visits conducted in their homes. The protocol was approved 
through the Johns Hopkins Institutional Review Board (IRB00115699) and launched on March 
2, 2018. Written informed consent was obtained from each participant prior to study enrollment. 
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The study was registered through ClinicalTrials.gov (NCT03452176). The Food and Drug 
Administration granted Scrambler therapy (FDA) 510(k) approval for acute, chronic and post-
operative pain, "Scrambler ST 5 TENS Device," (K081255) in February 2009 (FDA, 2009). 
Participants 
Participants with self-reported neuropathic pain caused by NMOSD were recruited 
through the Johns Hopkins Neuromyelitis Optica Clinic. For participation eligibility, patients 
were aged 18 years or older with an NMOSD diagnosis based on the 2015 international 
consensus diagnostic criteria (Wingerchuk et al., 2015), regardless of anti-aquaporin 4 (AQP4) 
serostatus (Wingerchuk et al., 2007; Ruiz-Gaviria et al., 2015). For inclusion, neuropathic pain 
needed to be attributable to an inflammatory spinal cord lesion, indicated by MRI from a 
previous clinical myelitis event. Persistent pain needed to be rated at a level of 4 or higher on an 
11-point numeric rating scale (NRS), with persistent pain defined by presence for >3 months. 
Patients needed to be stable in their disease, such that they had no spinal cord relapses within 6 
months prior to enrollment. Patients were eligible to use any combination of standard of care 
medications for pain treatment, including anti-epileptic, antidepressant, opioid or non-steroidal 
anti-inflammatory medications, with no adjustments to the regimen within 30 days of enrollment. 
Patients with a known or suspected concomitant diagnosis of peripheral neuropathy were 
excluded. Patients with an ongoing concomitant central neurologic disorder were excluded, as 
were those who used an investigational agent for pain control within 30 days of enrollment, were 
pregnant or breastfeeding, were cognitively or mentally incompetent, or had implantable pain 
management or arrhythmia devices. 
Randomization and Masking 
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Following consent and screening, participants were randomly assigned to receive 
Scrambler treatment versus sham at a 1:1 ratio for 10 consecutive weekdays. Recruitment was 
batched using a randomized block design stratifying across medication class (anti-epileptic, 
antidepressant, opioid or none) and pain level at screening (moderate 4-6, or severe 7-10) using 
blocks of four patients to promote similar distributions across groups in this small study. The 
rationale was to increase homogeneity between groups due to limited data that suggest response 
to Scrambler therapy may differ due to interference of medications used for pain (Moon et al., 
2015). Randomization assignments were assigned by a third-party utilizing 
www.randomizer.org. 
Scrambler therapy was administered via the GEOMC Pain Scrambler, model MC-5A. 
Electrodes were placed on participants receiving treatment within the dermatome above and 
below the level of injury, in a sufficiently sensitive area closest to the pain. For instance, if the 
patient had pain in the back from C3 to C8, a set of electrodes would be placed at C2 (above the 
pain) and T1 (below the pain.) Stimulation intensity was increased until a maximum tolerable 
threshold was reached without being painful, per the established protocol (Calmare Technologies 
Inc., 2008). If the patient felt a constant burn, sting or feeling of discomfort, electrodes were 
repositioned. The exact electrode positioning depended on the demarcation of the surface pain 
area, and analgesic response of the patient. Once the channel was regulated to the patient’s 
maximum intensity, pain was assessed by asking the patient how s/he felt in the area of pain 
covered by the electrodes and adjusted for desired effect of reduced pain and/or analgesic 
response. Additional channel-pairs were similarly implemented as necessary based on size of 
pain area, up to 5 pairs in total. Electrodes remained in the established position and intensity for 
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35 minutes from the time of proper placement was instituted. As central pain is often more 
pervasive as compared with peripheral neuropathy, more than one area was often targeted.  
For the sham group, small motors (<1 cm) which produce a vibratory sensation similar to 
a wearable activity tracker (i.e., FitBit) were connected to each electrode to simulate Scrambler 
stimulation but without electrical charge. Channel-pairs were similarly applied in a sufficiently 
sensitive dermatome closest to the pain, surrounding the level of spinal cord injury. The sham 
sensation was applied for 35 minutes. 
For both groups, the Scrambler machine was kept behind a curtain to help preserve 
masking. The machine itself was turned on for all participants, though without emitting any 
stimulation in those receiving sham, so that the alert indicating termination of treatment would 
be heard by all participants regardless of treatment assignment. Because treatment effect has 
been shown to vary across technicians (Moon et al., 2015), one technician was trained in the 
proper delivery of Scrambler treatment and performed all interventions.  
Study Objectives and Measures 
Our primary objective was to determine if Scrambler therapy is an effective, acceptable, 
feasible and safe treatment of persistent central neuropathic pain. The primary outcome was 
effectiveness at the end of the 10-day treatment period. This was evaluated based on degree of 
improvement in pain, comparing the treatment group to sham. Prior to initiation of Scrambler 
therapy and at completion of treatment, patients were asked to rate their pain by the 11-point 
NRS score. Patients additionally reported NRS pain scores at 30- and 60- days following therapy 
completion to assess sustainability of treatment effect. 
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Feasibility of treatment was examined to determine whether the intervention was 
appropriate for this patient population, toward the effort of informing a larger, Phase III study. 
This was measured by assessing the following: 1) adherence to visit schedule and 2) response to 
the following question asked directly after completion of the 10-day treatment period: “Do you 
think you received treatment?” (Yes/No). Acceptability was measured by assessing response to 
the following question, also asked directly following the treatment course: “Would you want to 
continue treatment in clinic, if available?” (Yes/No). 
Safety of the intervention was evaluated by comparing Adverse Events (AEs) and Serious 
Adverse Events (SAEs) in the treated versus sham groups. These were monitored and 
documented prior to initiation of each treatment daily, at termination of final treatment, and at 
30- and 60-day follow-up.   
Although not powered appropriately, an exploratory objective aimed to assess the 
relationship between improved pain and other co-occurring symptoms. Prior to initiation of 
Scrambler therapy, patients were asked to complete each of the following measurement tools to 
determine baseline pain severity and interference, anxiety, depression, and sleep disturbance, 
respectively: Brief Pain Inventory (BPI) (Cleeland, 2009), Neuro-QoL [Quality of Life in 
Neurological Disorders] Short Form v1.0 - Anxiety, Neuro-QoL Short Form v1.0 - Depression, 
and Neuro-QoL Short Form v1.0 - Sleep Disturbance (Cella et al., 2011). Measurement tools 
were accessed by participants via a secure online portal. Participants were provided with an 
alphanumeric code that enabled their responses to be linked to their demographic and clinical 
data in a confidential manner. Questionnaires were mailed to participants without internet access 
with a postage-paid envelope provided for return of questionnaires. Patients again completed all 
measurement tools at end of treatment, and at 30- and 60-days following end of treatment.  




Effectiveness was based on degree of improvement of pain and compared NRS pain 
scores in the treatment group and sham group using the Friedman One-Way Repeated Measure 
Analysis of Variance by Ranks test at baseline, following treatment, and at 30- and 60-day 
follow-up. Wilcoxon signed-rank testing was used to determine sustainability over time by 
comparing scores at baseline to those following treatment, at 30-day follow-up and at 60-day 
follow-up. A chi-squared analysis comparing the number of treated patients who thought they 
received treatment versus the number of sham patients who thought they received treatment was 
performed to determine if masking was effective.  
The target sample size of 22 (11 per arm) was based on previous studies which suggest 
that the average pain value at baseline is at least 4 on the 0-10 NRS with a standard deviation of 
the original pain value expected to fall in the range of 1-1.5 in this patient population (Majithia et 
al., 2016; Park et al., 2017; Ricci et al., 2011; Pachman et al., 2015; Smith et al., 2010; Marineo 
et al., 2012). A conservative estimate of the standard deviation of the change across patients from 
Day 1 to Day 10 was approximately up to 2. With 11 patients in each arm and under these 
assumptions, we were able to detect a change of 2.5 points in the Scrambler group at 80% power, 
with a difference in proportions of 60% between the two groups.  
As one measure of feasibility of treatment, adherence to visit schedule was ascertained. 
We report the number of patients in each group who were able to complete all treatments. 
Fisher’s exact test was performed to assess if adherence is independent of group assignment. For 
each of the two survey questions used to assess feasibility and acceptability, as described above, 
a 95% confidence interval for the proportion of participants answering “Yes” was calculated. 
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Given the small number of patients in the study, exact binomial confidence intervals were 
calculated since normal distribution could not be assumed.  
Descriptive statistics were used to report AEs and SAEs. Incidence and severity were 
compared between groups.  
To explore the impact on co-occurring symptoms when intervening on pain, scores were 
tabulated for each of the following based on measurement tool data: anxiety, depression, sleep 
disturbance and pain interference. Friedman One-Way Repeated Measure Analysis of Variance 
by Ranks was tabulated for each symptom, comparing the change at baseline, following 
treatment, and at 30- and 60-day follow-up timepoints in each arm. A subanalysis was similarly 
conducted in those patients who “responded” to Scrambler treatment versus sham. Based on a 
cohort of adult patients with spinal cord injury who reported clinically meaningful change in pain 
over time (Hanley et al., 2006), “response” was defined as patients with a decrease in NRS pain 
scores of 1.80 points between baseline and end of treatment.  
Demographic and clinical characteristics were compared between Scrambler and sham 
groups using Mann-Whitney U and Chi-squared testing, as appropriate. 
Data Availability 
Public Law 110-85 (also known as the FDA Amendments Act of 2007) mandates 
registration and results reporting of "applicable clinical trials" in ClinicalTrials.gov. We support 
efforts to promote data sharing toward the advancement of science and registered this clinical 
trial, providing trial design, eligibility criteria and outcomes measures. 
Classification of Evidence 
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This study provides Class 1 evidence of Scrambler therapy use in patients diagnosed with 
NMOSD who have central neuropathic pain.  
Results 
Twenty-two patients (11 per arm) who were deemed eligible for participation in this 
clinical trial were enrolled, treated and received follow-up between March and December 2018 
(Figure 1). Participants were treated with Scrambler therapy or sham. Most patients were female 
(91%) and African American (59%). All participants were seropositive for AQP4 IgG. The 
median baseline NRS pain level was 5 points for both the treatment and sham groups 
(mean=5.6). The median Expanded Disability Status Scale (EDSS) score was 6.0 and 4.5 for the 
treatment and sham groups, respectively. Patient characteristics were similar between groups 
(Table 1).  
Effectiveness Outcomes 
The effectiveness of Scrambler therapy was determined by the impact on pain over time 
in the treatment group compared to the sham group, as measured by the NRS pain score. NRS 
pain scores were recorded at baseline, immediately following treatment versus sham, and at 30- 
and 60-days following treatment versus sham. Following the 10-day protocol, Scrambler therapy 
resulted in a reduction in median NRS pain scores from 5.0 to 1.5 (p<0.001), whereas the sham 
condition resulted in a reduction in median NRS pain scores from 5.0 to 4.0 (p=0.4239) (Figure 
2). In the Scrambler therapy arm, eight of 11 participants had a clinically meaningful 
improvement in pain, with four participants experiencing complete pain eradication immediately 
following the protocol, (Figure 3). NRS pain scores remained significantly decreased at 30 days 
in the Scrambler-treated group (p=0.0195). However, the effect was not sustained at 60 days 
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(p=0.0518). Because of this, a post hoc power calculation was conducted based on current study 
data to determine the sample size needed to detect a change in this secondary endpoint for use in 
a larger Phase III trial. It was determined that 29 patients per arm would be necessary, given a 
mean 60-day score of 4.07 in the Scrambler treated arm and 5.32 in the sham arm with a standard 
deviation of 1.89. 
Feasibility/Acceptability Outcomes 
There was no difference between groups in the number of participants who completed all 
treatments (p=0.22). All participants in the treatment arm completed all treatments, and two 
participants in the sham arm completed only 9 of 10 sessions: one patient experienced a family 
emergency and the other had a urinary tract infection that interfered with the trial. A chi-squared 
analysis revealed that masking of the intervention was adequate, as there was no difference 
found between those in the treated group who thought they received Scrambler therapy versus 
those in the sham group who thought they received therapy (p=0.20; 95% CI 0.91 to 5.04). 
Additionally, a chi-squared analysis also suggested that those who received the sham 
intervention were equally likely to want to continue treatments as those who received treatment 
(p=0.67; 95% CI 0.56 to 3.61).  
Safety Outcome 
All AEs were logged daily prior to and following each treatment, as well as at 30- and 
60-day follow-up (Table 2). There were no SAEs reported during the 10-day treatment period 
among participants in either study arm. During follow-up, two SAEs were reported within the 
same patient: Patient 3 (sham arm) developed a port and bloodstream infection 30 days after 
completion of the 10-day sham course requiring hospitalization for IV antibiotic treatment. 
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Because the infection was unresolved, the patient was re-hospitalized 30 days later for IV 
antibiotics. Given the temporal profile and fact that the patient did not receive Scrambler 
treatment, these infections were not thought to be related to the study. Neither Scrambler therapy 
nor the sham condition resulted in increased pain severity in these trial participants. 
Exploratory Outcome 
The median depression T score in the treatment arm significantly decreased following 
treatment with Scrambler therapy (p=0.03). There were no significant decreases in anxiety 
(p=0.10), sleep disturbance (p=0.26) or pain interference (p=0.37) following Scrambler 
intervention (Figure 4). In the Scrambler therapy arm, eight participants had a clinically 
meaningful improvement in pain, based on a decrease in NRS pain score of 1.80 or greater. 
When considering only these patients, the change in median anxiety T scores becomes 
significant (p=0.02), while sleep disturbance and pain interference remain unchanged (p=0.64 & 
p=0.68, respectively). Among those in the sham arm, the median anxiety, depression and sleep 
disturbance T scores did not change over time (p=0.15, p=0.60, p=0.36, respectively). Four 
participants had a clinically meaningful improvement in pain in the sham arm. When considering 
only these patients, all symptoms remain unchanged over time.  
Discussion 
Results of this sham-controlled trial in patients with NMOSD demonstrate that Scrambler 
therapy is an effective and safe intervention for central neuropathic pain. Participants who 
received Scrambler therapy had a significant reduction in pain, as compared to those who 
received sham. This was sustained at 30 days following the treatment course. Notably, there was 
no difference in the number of patients who thought they were assigned to the treatment versus 
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sham groups, which suggests that any placebo effect was controlled for through the established 
sham intervention. To date, most research investigating the effect of Scrambler therapy on pain 
has involved open label trials for peripheral neuropathic pain management (Smith et al., 2017; 
Joo et al., 2017; Park et al., 2017; Kim et al., 2017; Sabato et al., 2005; Notaro et al., 2016). Four 
studies have utilized a random controlled design, including two unblinded prospective 
randomized trials that tested Scrambler therapy against an active comparator (Loprinzi et al., 
2018; Marineo et al., 2012), and two that have applied a blinded, randomized, sham-controlled 
design. One involved patients with chemotherapy-induced peripheral neuropathy, which found 
no difference, when compared to Scrambler therapy placed on the back near the spine (n=14) 
(Campbell et al., 2013). In the second prospective, placebo-controlled trial, tested in patients 
diagnosed with low-back pain (n=30), the treatment group was found to have a significant 
reduction in pain compared to the control group (Starkweather et al., 2015). The sham group 
received Scrambler therapy, at what was thought to be subtherapeutic doses.  
 Results suggest the trial is feasible and acceptable. Adherence with the full program 
comprising 10 sequential weekday visits was similar in both groups, and there was no difference 
in the number of participants who completed the trial and follow up in both groups. Both groups 
also reported an interest in continuing treatments beyond the trial period indicating a strong 
desire for pain relief using non-medical therapies. Because many of our NMOSD participants 
were severely disabled and unable to commute to the clinic on a regular basis, we offered home 
treatment in both arms. This likely improved feasibility and protocol adherence and suggests that 
a study that enables home treatments would make NMOSD participant enrollment and retention 
easier for a larger study. 
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This is the first prospective, interventional trial of a therapy to treat pain in patients with 
NMOSD to be reported, as well as the first to investigate Scrambler therapy specifically for 
central neuropathic pain. The rationale for Scrambler use in patients with NMOSD involves the 
peripheral sensitization of non-myelinated ascending C fibers, the slightest stimulation of which 
are interpreted by the brain as persistent pain (Pellkofer et al., 2013). In addition to evidence that 
Scrambler therapy improves pain from peripheral neuropathy, investigation into Scrambler 
therapy in patients with central neuropathic pain syndromes has been limited to two case studies 
(hemorrhagic brainstem cavernoma and transverse myelitis) prior to our study, both of which 
reported improvement in pain (D’Amato et al., 2018; Mealy et al., in press).  
Opioids are frequently employed for breakthrough therapy in patients with NMOSD 
given the severity and intensity of pain in this population. Doses and numbers of medications are 
often increased due to opioid tolerance, causing side effects, particularly at higher doses, which 
are independently associated with fatigue (Qian et al., 2012). With growing awareness of the 
dangers of polypharmacy, Scrambler therapy provides a non-pharmacologic option for central 
neuropathic pain treatment. Advancing alternative mechanisms for pain treatment including 
Scrambler therapy may allow for reduced medication dosing such that other symptoms with 
which the patient is already struggling are not exacerbated.  
Recent research in chronic disease suggests that treating one symptom in isolation of 
other co-occurring symptoms does not impact QoL (Kim et al., 2013). However, small studies 
specific to patients with NMOSD indicate that treating pain may have the greatest impact on 
improving QoL (Mealy et al., 2016; Mealy et al., in press). While the current study did not 
measure QoL, the findings suggest that among those who responded to Scrambler therapy, 
intervening on pain decreases depression and anxiety, which may, in turn, impact QoL.  
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This study was limited by several factors. First, the design of this study was single-
blinded due to the fact that the technician knew if treatment or sham was being delivered by 
necessity. To mitigate the bias this potentially introduced, measurement tools and survey data 
were collected by an unrelated study coordinator. Second, though patients were recruited using a 
randomized block design to mitigate risk of confounding effects from pain medication class 
based on previous data which reported that the type of medication may be predictive of response 
to Scrambler therapy (Moon et al., 2015), our study was not powered to sufficiently compare 
efficacy results across classes of pain medications since patients were often on multiple 
medications. Lastly, this study was not powered to effectively examine sustainability of 
treatment, which was not sustained through the 60-day follow-up period. However, the trend 
toward significance at 60 days (p=0.0518) suggests that a larger study that includes 29 patients 
per arm may uncover sustained effect. The effect that modifying pain through Scrambler therapy 
had on co-occurring symptoms was also limited by the sample size. The effectiveness, feasibility 
and safety profiles we report support the need for a larger Phase III study to further examine the 
effect of Scrambler on pain, co-occurring symptoms and quality of life in a larger NMOSD 
patient cohort.   
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Lost to follow-up (n=0)
Discontinued intervention (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Allocation
Allocated to intervention (n=11)
•Received Scrambler therapy 
(n=11)
Allocated to sham (n=11)
•Received sham (n=11)
Randomized (n=22)
Assessed for eligibility (n=23)
Excluded (n=1; declined to participate)
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Figure 2: Box and whisker plots depicting median change in NRS pain scores across time points 
in A) Scrambler treated and B) sham arms. 
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Figure 3: Patient response by arm at end of 10-day treatment. Complete response (NRS=0), 
partial response (decrease in NRS >1.8 but not rated at 0), no response (decrease in NRS <1.8): 
A) Scrambler therapy intervention. Median decrease in NRS was 4 points in “partial 
responders” and 1.5 points in “non-responders”. 
B) Sham intervention. Median decrease in NRS was 3.5 points in “partial responders” and -
0.5 point in “non-responders”. 






complete response: 4 (36%)
partial response: 4 (36%)
no response: 3 (27%)
Sham
complete response (0)
partial response: 5 (45%)
no response: 6 (55%)
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Figure 4: Box and whisker plots depicting median change in A) depression, B) anxiety, C) sleep 
disturbance and D) pain interference scores for Scrambler treated and sham arms. 
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Table 1. Demographic and clinical characteristics of participants 
 Treatment Sham p-value 
Participants 11 11 1.0 


































































































*AQP4=aquaporin 4; EDSS=Expanded Disability Status Scale; NRS=numeric rating scale; AEDs=antiepileptic drugs 
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ongoing Moderate None 
Not related 
02 4/2/2018 4/13/2018 5/14/18 6/10/18 None N/A N/A N/A N/A N/A 
05 6/4/2018 6/15/2018 7/14/18 8/11/18 None N/A N/A N/A N/A 
N/A 
06 6/11/2018 6/22/2018 7/23/18 8/17/18 None N/A N/A N/A N/A 
N/A 





7/11/18 Mild None  
Not related 








7/27/18 Moderate  None 
Related 
10 7/23/2018 8/3/2018 8/30/18 9/28/18 None N/A N/A N/A N/A N/A 
11 8/6/2018 8/17/2018 9/27/18 10/15/18 None N/A N/A N/A N/A N/A 
17 9/10/2018 9/21/2018 10/23/18 12/1/18 None N/A N/A N/A N/A N/A 
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19 9/24/2018 10/5/2018 11/10/18 12/4/18 None N/A N/A N/A N/A N/A 
22 10/8/2018 10/19/2018 11/28/18 12/20/18 None N/A N/A N/A N/A N/A 
Sham 





















4 5/7/2018 5/18/2018 6/18/18 7/13/18 None N/A N/A N/A N/A  N/A 
8 7/9/2018 7/20/2018 8/23/18 9/19/18 None N/A N/A N/A N/A N/A 
12 7/23/2018 8/3/2018 9/10/18 10/16/18 None N/A N/A N/A N/A N/A 
13 




10/1/18 Moderate Oral ABX 
Not related 
14 8/20/2018 8/31/2018 10/15/18 11/7/18 None N/A N/A N/A N/A N/A 
15 8/20/2018 8/31/2018 10/3/18 11/8/18 None N/A N/A N/A N/A N/A 
16 9/3/2018 9/19/2018 10/18/18 11/19/18 None N/A N/A N/A N/A N/A 
18 





9/14/18 Moderate Oral ABX 
Not related 
20 9/24/2018 10/5/2018 11/8/18 12/3/18 None N/A N/A N/A N/A N/A 
21 9/24/2018 10/5/2018 11/15/18 12/5/18 None N/A N/A N/A N/A N/A 
*AE=adverse events; ABX=antibiotics; UTI=urinary tract infection
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Pain is a highly prevalent and severely disabling component of neuromyelitis optica spectrum 
disorder (NMOSD) that affects quality of life. The aim of this study was to determine the impact 
of pain on other co-occurring symptoms in persons with NMOSD. This cross-sectional analysis 
investigates the impact of pain on other symptoms that occur in patients with NMOSD, including 
anxiety, depression and sleep disturbance, as well as QoL. Seventy-two participants who were 
obtained through convenience sampling completed each of the following surveys to determine 
pain, health-related QoL, anxiety, depression and sleep disturbance, respectively: Brief Pain 
Inventory (BPI), Short Form-36 Health Inventory (SF-36), Neuro-QoL [Quality of Life in 
Neurological Disorders] Short Form v1.0 – Anxiety, Neuro-QoL Short Form v1.0 – Depression, 
and Neuro-QoL Short Form v1.0 - Sleep Disturbance. Pain was shown to correlate with physical 
components of QoL, fatigue, anxiety and sleep disturbance. However, degree of anxiety and 
sleep disturbance were similar in this patient cohort when compared to normative data. These 
data add to the body of evidence that pain may be the primary contributor of components that 
lead to poor QoL in patients with NMOSD.   
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Pain severity associates with poor quality of life in patients with neuromyelitis optica spectrum 
disorder 
 Neuromyelitis optica spectrum disorder (NMOSD) is a recurrent autoimmune disease that 
primarily targets the optic nerves and spinal cord, leading to blindness and immobility. 
Neuropathic pain due to inflammatory damage of the spinal cord is a highly prevalent and 
disabling component of the disease, with 83-91% of patients reporting its presence in descriptive 
studies (Kanamori et al., 2011; Qian et al., 2012; Pellkofer et al., 2013). Half of patients with 
NMOSD characterize their pain as severe and two thirds report being in constant pain (Zhao et 
al., 2014; Pellkofer et al., 2013). Research on the impact of persistent pain on quality of life 
(QoL) in NMOSD has found that pain is associated with depression, reduced enjoyment of life, 
and increased difficulty with ambulation (Mutch et al., 2014; Pellkofer et al., 2013; Zhao et al., 
2014). Pain, mood, and mobility are the best predictors of poor QoL, and pain may be the 
strongest independent predictor (Kong et al., 2016; Mealy et al., 2018). In fact, pain predicts 
poor QoL better than disability, despite the profound impact NMOSD is known to have on 
neurologic function (Kong et al., 2016).  
 Treating multiple interrelated symptoms is more likely to improve QoL in chronic 
diseases (Kim et al., 2013). However, researchers are just beginning to understand the 
complexity of such relationships among symptoms and their effect on QoL in NMOSD. 
Preliminary evidence prompted the need to fully explore the interrelatedness of these frequently-
occurring symptoms in NMOSD, and their effect on QoL. Because of its pervasiveness, 
investigating the impact of pain on these co-occurring symptoms, including anxiety, depression 
and sleep disturbance, as well as QoL, may offer health care providers a deeper understanding of 
how to approach comprehensive symptom management in this population.  




 This is a cross-sectional descriptive analysis of symptoms data collected from patients 
diagnosed with NMOSD. Participants were recruited through the Johns Hopkins NMO Clinic 
and through a social media support group for patients with NMOSD. All patients aged 18 years 
and older who fulfilled the 2015 International Panel for NMO Diagnosis (IPND) criteria were 
eligible for participation (Wingerchuk et al., 2015), regardless of pain status. The study was 
broadly presented to potential participants as an investigation into symptoms experienced by 
patients with NMOSD, so as to not deter data capture from patients who are pain-free. Following 
written informed consent, health records were obtained for review and data acquisition. A 
neurologist (ML) confirmed the diagnosis in those patients recruited through the social media 
site who were not evaluated in person at Johns Hopkins. Demographic and clinical data were 
extracted from all patient records. Participants were asked to access a secure online portal to 
complete a series of surveys and were provided with an alphanumeric code that enabled the 
study team to link participants’ data in a confidential manner. For this cross-sectional 
assessment, participants completed each of the following surveys to determine pain, health-
related QoL, anxiety, depression and sleep disturbance, respectively: Brief Pain Inventory (BPI; 
Cleeland, 2009), Short Form-36 Health Inventory (SF-36; Ware, Snow, & Kosinski, 1994), 
Neuro-QoL [Quality of Life in Neurological Disorders] Short Form v1.0 – Anxiety, Neuro-QoL 
Short Form v1.0 – Depression, and Neuro-QoL Short Form v1.0 - Sleep Disturbance (Cella et 
al., 2011). The study was approved by Johns Hopkins Institutional Review Board 
(IRB00065696). 
Measurement Tools 
PAIN IN NMOSD   
105 
 
 BPI was an initiative of the National Cancer Institute and the World Health Organization 
in response to the need for better capture of the severity and impact of cancer pain and as a way 
to quantify improvement in pain after changes to analgesic therapy were made (Cleeland, 2009). 
It has been validated in dozens of persistent pain conditions and is among the most widely used 
tools in NMOSD research to date (Zhao et al., 2014; Kanamori et al., 2011). Separate scores for 
pain severity, based on a patient-reported 11-point numeric rating scale (NRS), and pain 
interference can be tabulated. Pain interference measures the patient-reported consequences of 
pain on relevant aspects of one's life, including the extent to which pain has interfered with seven 
daily activities, including general activity, walking, work, mood, enjoyment of life, relations with 
others, and sleep (Cleeland, 2009). Both the pain severity and interference scales are scored from 
0 to 10, where 0 indicates no pain/pain interference, and these dimensions grow increasingly 
worse as they approach ten.   
The Medical Outcomes Study Short Form-36 Health Inventory (SF-36) is a patient-
reported survey of overall patient health-related quality of life for which normative data are 
available (McHorney, Ware, Lu, & Sherbourne, 1994). It has been widely used for QoL 
assessment in chronic conditions, including in NMOSD research (Qian et al., 2012; Zhao et al., 
2013; Pellkofer et al., 2014; Kanamori et al., 2011). Scores for eight sub-scales can be tabulated, 
and include physical components (physical function, physical role limitations, pain), mental 
components (emotional role limitations, emotional wellbeing, social function), and general 
components (energy/fatigue, general health) (Ware, 1994). Unlike with other measures, higher 
scores represent better functioning.  
Neuro-QoL was established by the National Institutes of Health and is a measurement 
system that evaluates and monitors the physical, mental, and social effects experienced by adults 
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and children living with neurological conditions (Cella et al., 2011). For data analysis, raw scores 
are rescaled into T-score distributions in order to standardize scores with a mean of 50 and a 
standard deviation of 10 for data analysis. A higher T-score represents more of the concept being 
measured, i.e., worse anxiety, depression, sleep disturbance. Normative data for anxiety and 
depression were derived based on the general U.S. population, and sleep disturbance was derived 
based on clinical populations (Ware, 1994).  
Statistical Analysis 
For this analysis, patients were binned into three categories based on their BPI pain 
severity score, mild (0-2), moderate (3-6) and severe (7-10). Non-parametric descriptive statistics 
were utilized to report demographic and clinical characteristics of the cohort. Each of the eight 
sub-scales of the SF-36 and all measures of co-occurring symptoms, as described above, were 
converted into a quantifiable score (Ware, 1994; Cleeland et al., 2009; NINDS User Manual 
Neuro-QoL, 2015). Patients were compared across the pain severity categories (mild, moderate 
and severe) for impact on QoL functionality and degree of anxiety, depression, sleep disturbance 
and pain interference using Kruskal-Wallis One-Way Analysis of Variance. Mean scores for the 
Neuro-QoL measurements of anxiety, depression and sleep disturbance in this cohort of patients 
with NMOSD were additionally compared with established normative data from general or 
clinical populations using two-sample t-tests. A global SF-36 score averaged the eight sub-scales 
and was used for a post hoc analysis to compare functioning across pain severity categories. 
Once a difference between two or more pain severity categories was established via Kruskal-
Wallis testing, a Dunn’s multiple comparisons test uncovered where these differences existed. 
Results 
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Seventy-two patients met study criteria and provided complete data sets. Ten additional 
patients were screened but were ineligible for participation due to failure to meet the 2015 IPND 
criteria. As expected, most participants were female (90.3%). Median age at the time of data 
capture was 56.1 years. Ninety percent of this cohort was seropositive for the highly specific 
aquaporin 4 (AQP4) antibody associated with NMOSD. Disease duration was a median 6.0 years 
and delay in diagnosis was a median 6 months. Eighty-nine percent of patients reported some 
degree of pain, with 22 (31%) participants binned into the category containing patients with no to 
low pain, 23 (32%) participants in the moderate pain severity category and 27 (37%) participants 
in the high pain severity category. The degree of pain was independent of a history of myelitis, 
duration of disease, AQP4 serostatus and delay in diagnosis. Demographic and clinical profiles 
were similar across categories (Table 1).  
Among the SF-36 sub-scales, those in the higher pain severity category were more likely 
to endorse lower functioning for all three physical components: physical mobility (p=0.01), 
physical role limitations (p=0.008), and, as expected, pain (p=0.0005) (Table 2). The effect of 
pain severity on SF-36 sub-scales that measure general components of functionality were split, 
such that those with higher pain severity endorsed low functioning due to energy/fatigue 
(p=0.008), but this was not the case for general health (p=0.058). Although the mental 
components of the SF-36 subscales did not significantly vary across different pain severity 
categories, there was a trend towards worsening emotional role limitations, wellbeing and social 
function with increasing pain severity. Given that there was a difference in functioning across 
pain severity categories, a post hoc analysis was conducted using a global SF-36 score. A 
significant difference in functioning was found between 2 or more pain severity categories 
(p=0.00143). Specifically, the difference was observed between low and moderate pain severity 
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categories (p=0.048) as well as low and high (p=0.0006), but not between moderate and high 
pain categories (p=0.413).    
Patients in the moderate and high pain severity categories also reported more anxiety 
(p=0.05) and sleep disturbance (p=0.001) on the Neuro-QoL assessment, and pain interference 
increased with pain severity as well (p<0.0001). Depression was similar across pain severity 
categories (p=0.115) (Table 3). While pain severity worsens the physical impact, patients with 
NMOSD do not have higher rates of depression, anxiety or sleep disturbance compared with 
available normative data (Ware et al., 1994) (Table 4). 
Discussion 
Our study, in a cohort of patients with a median duration of disease of 6 years, is among 
the largest descriptive studies to assess the relationship of pain with co-occurring symptoms and 
components of quality of life in NMOSD. Results indicate that pain is present in the vast 
majority of patients with NMOSD, 89%, which concurs with previous investigations (Qian et al., 
2012; Pellkofer et al., 2013). Patients with more severe pain have decreased functionality in SF-
36 components of physical health and energy/fatigue. Low pain is associated with better quality 
of life function, whereas moderate and severe pain appear to equally impact functioning. 
Likewise, those in the low pain severity category endorse better anxiety and sleep outcomes 
among patients with NMOSD, whereas moderate and severe pain appear to equally affect these 
outcomes, as measured by Neuro-QoL. This suggests that both moderate and severe pain are 
equally impactful on QoL and co-occurring symptoms. Reducing pain may contribute to the 
treatment of other co-occurring symptoms, including anxiety, depression and sleep disturbance. 
As depression in the NMOSD population is under-recognized and undertreated with higher 
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levels of suicidality (Chavarro, et al., 2016), addressing pain in these patients may enable better 
emotional wellbeing functioning.  
This is the first study to compare the amount of depression, anxiety and sleep 
disturbances in patients with NMOSD to normative data and found no differences. This 
interesting finding in a population that experiences persistent pain may suggest remarkable 
resiliency, particularly when coupled with the finding that mental and social functioning was not 
significantly impacted by pain within patients with NMOSD. Because some patients were 
recruited through an online social media support group, self-perceptions of functionality may be 
influenced by access to communal support in this rare disease and may contribute to enhanced 
resiliency. While the current study cannot address this finding, it deserves further exploration in 
future analyses of patients with NMOSD, particularly given that other research in NMOSD has 
reported a reduction in mental and social functioning due to pain (Zhao et al., 2014).  
Collectively, our results implicate pain as a possible to many components that interfere 
with QoL, as characterized by declines in physical and general health. Supporting this contention 
is the finding that quality of life significantly differs in patients with NMOSD based on their pain 
severity. These data add to the body of evidence that pain may be the primary driver of many 
components that collectively contribute to poor QoL in patients with NMOSD, though 
longitudinal studies are needed to confirm this. It is worth noting that pain severity correlates 
highly with pain interference. This is important since pain severity can be quickly captured in the 
course of a busy clinic day, but it is only of value if it appropriately reflects how pain is affecting 
a patient on a daily basis outside of the clinic. This study suggests that acquiring a simple NRS 
pain score may act as a reliable surrogate of overall QoL in NMOSD patients.  
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There are three important limitations to this study worth noting. First was the inability to 
collect disability data. Because not all patients were seen in person, a disability score could not 
be ascertained uniformly across all participants. As disability accumulates in NMOSD with each 
attack, delay in diagnosis and delay in initiation of preventive therapy has been shown to act as a 
surrogate for disability in patients with NMOSD (Mealy et al., 2018). While there was no 
difference in diagnostic delay across pain severity categories, a more direct capture of disability 
would be beneficial in future investigations. A second limitation regards the sample evaluated. 
While all patients seen at the Johns Hopkins NMO Clinic or who belong to the social media 
support group were invited for inclusion into this study, participation bias may influence those 
who chose to participate, thus affecting the representativeness of the NMOSD population as a 
whole. Lastly, while the cross-sectional study design enabled data collection in a relatively large 
number of patients for this rare disease, it does not define the direction of relationships. While 
other disease states report a bidirectional relationship (Amtmann et al., 2015), it is yet unknown 
whether patients with increased anxiety and/or poor sleep quality are more likely to report higher 
levels of pain, or whether pain severity increases anxiety and sleep disruption in this population. 
A comprehensive longitudinal investigation into the degree of change in co-occurring symptoms 
reported by patients in response to a pain intervention may be necessary to further clarify the 
complexity of these relationships in patients with NMOSD.    
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Table 1: Demographic and clinical characteristics of participants 










Participants (n=72) 22 23 27 N/A 





























































AQP4 seropositive 18 (82%) 20 (87%) 27 (100%) 0.13 
History of myelitis 18 (82%) 21 (91%) 26 (96%) 0.23 
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Table 2: Effect of pain severity category on health-related QoL, measured by SF-36 sub-scales 
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Table 3: Effect of pain severity category on co-occurring symptoms, measured by Neuro-QoL 
anxiety, depression, sleep disturbance scales, and BPI pain interference 
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Table 4: Comparing Neuro-QoL anxiety, depression, sleep disturbance scales in patients with 
NMOSD to normative U.S. data  
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Chapter 5: Synthesis/Discussion 
 The studies herein examined pain in patients with neuromyelitis optica spectrum disorder 
(NMOSD). Specifically, we investigated the use of Scrambler therapy for treatment of central 
neuropathic pain and explored whether reducing pain in this population could improve co-
occurring symptoms and quality of life (QoL). Given the interrelatedness of symptoms, as 
outlined by the Theory of Unpleasant Symptoms (TOUS; Lenz et al., 1997), pain reduction and 
improvement in co-occurring symptoms may have a clinically meaningful impact to patients’ 
physical, social and emotional functioning.  
Pain has been shown to interfere with QoL and may be the best independent predictor of 
poor QoL in NMOSD (Kong et al., 2016; Mealy et al., 2018). Central neuropathic pain (CNP) is 
particularly severe, pervasive and intractable to available treatments (Zhao et al., 2014). This is 
the first interventional pain trial in the United States to be conducted in patients with NMOSD, 
and the first to announce results worldwide. It is also the first trial to examine Scrambler use in 
patients with CNP. Results from this study may guide health care providers with non-
pharmacologic approaches for comprehensive symptom management in this population. 
Furthermore, while treatment of severe pain was a particular unmet need in the NMOSD patient 
population, the knowledge gained from this investigation may be applicable to other more 
common conditions that cause CNP, including multiple sclerosis, spinal cord injury and stroke. 
Summary of Findings 
 Two studies were conducted in parallel. The synthesis of results from these will help to 
implement a well-informed Phase III randomized sham-controlled trial where the results are 
more likely to decrease pain in patients with NMOSD. Importantly, the data captured suggests 
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that reduction in pain will meaningfully impact the quality of lives in the target population. 
Targeting pain without considering the effect on QoL may yield a statistically significant 
reduction in pain without translating into enhanced QoL. This is especially true in light of 
chronic disease research that suggests that improving a single symptom in diseases where other 
symptoms are common without considering these co-occurring symptoms may not impact QoL 
(Kim et al., 2013). As such, the rationale for this two-pronged approach was to gain insights for 
future studies that are more likely to yield clinically meaningful results.  
 The first two aims of the dissertation utilized a cohort of 22 patients with NMOSD who 
have CNP and were recruited from the Johns Hopkins NMOSD Clinic. Patients were randomized 
1:1 and blinded to undergo either Scrambler or sham therapy daily for 10 consecutive weekdays.  
Aim 1 
The goal of Aim 1 was to investigate the effectiveness, safety, acceptability and 
feasibility of Scrambler therapy when compared to sham.  
Sub-aim 1. Feasibility and acceptability were measured based on response to a brief patient 
survey presented to patients following treatment, as follows, comparing Scrambler-treated 
patients to those in the sham arm: “Do you think you received treatment?” (Yes/No), and 
“Would you want to continue treatment in clinic, if available?” (Yes/No). Feasibility was further 
measured based on patient adherence to the study visit schedule, comparing those in the 
Scrambler arm to the sham arm. Results from this aim found no difference between groups in 
patients who thought they received treatment, as well as no difference in whether they would 
want to continue such treatment. Most patients completed all treatments, with no difference 
found between arms. 
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Sub-aim 2. Safety of the intervention was evaluated by comparing Adverse Events (AEs) and 
Serious Adverse Events (SAEs) in the treated versus sham groups. Safety profiles were similar 
between the Scrambler-treated arm and the sham arm, with one participant in the sham arm 
experiencing SAEs related to infections during the follow-up period. Pain did not increase in 
either group. 
Sub-aim 3. Effectiveness of Scrambler therapy was evaluated by comparing change in numeric 
rating scale (NRS) pain scores from baseline to end of treatment between the Scrambler treated 
and sham arms. The median baseline NRS pain score decreased from 5.0 to 1.5 following 10 
days of treatment with Scrambler therapy, whereas the median NRS score did not significantly 
decrease in the sham arm. This effect was sustained at 30 days following treatment, though not at 
60 days. 
Aim 2 
 The goal of Aim 2 was to explore the effect of Scrambler therapy on co-occurring 
symptoms, including pain interference, anxiety, depression and sleep disturbances, comparing 
patients in the Scrambler-treated arm to those in the sham arm. Prior to initiation of Scrambler 
therapy, patients were asked to complete each of the following measurement tools to determine 
baseline pain severity and interference, anxiety, depression, and sleep disturbance, respectively: 
Brief Pain Inventory (BPI), Neuro-QoL [Quality of Life in Neurological Disorders] Short Form 
v1.0 - Anxiety, Neuro-QoL Short Form v1.0 - Depression, and Neuro-QoL Short Form v1.0 - 
Sleep Disturbance (Cleeland, 2009; Cella et al., 2007). Non-parametric testing revealed that 
depression scores were reduced from baseline in the Scrambler-treated group only. A subanalysis 
that only considered patients who responded to treatment found a decline from baseline in 
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anxiety in Scrambler-treated patients as well. Symptoms were unchanged in patients receiving 
sham treatment.  
In parallel with this aim, a third aim of this dissertation involved a cross-sectional 
investigation in 72 patients diagnosed with NMOSD who were recruited via convenience 
sampling through the Johns Hopkins NMO Clinic and an online social media patient support 
group. This included data from the 22 patients in the Scrambler study at their baseline timepoint. 
Aim 3 
 The goal of Aim 3 was to assess the impact of pain on other symptoms that co-occur in 
patients with NMOSD, including anxiety, depression and sleep disturbance, as well as QoL. 
Patients accessed Brief Pain Inventory (BPI; Cleeland, 2009), Neuro-QoL [Quality of Life in 
Neurological Disorders] Short Form v1.0 - Anxiety, Neuro-QoL Short Form v1.0 - Depression, 
Neuro-QoL Short Form v1.0 - Sleep Disturbance (Cella et al., 2007) and Short Form-36 Health 
Inventory (SF-36; Ware et al., 1994) via a secure online portal. While on average patients with 
NMOSD do not have higher amounts of depression, anxiety or sleep disturbance compared with 
available normative data, our data revealed that patients with moderate and high pain severity 
were more likely to endorse lower functioning and higher anxiety and sleep disturbance than 
those patients with low or no pain.  
Discussion 
Strengths and Limitations 
This study was innovative in three crucial ways, as discussed below: 
1. It addressed the important and severe problem of pain in an undertreated population. 
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2. It provided proof-of-concept for treatment of CNP that may be applicable to other 
etiologies, in addition to NMOSD. 
3. It added to the body of knowledge for conducting sham-controlled studies using 
Scrambler therapy. 
Although NMOSD is a rare disease, it is devastating for those who have it. The pain experienced 
by this population of patients is particularly refractory to available treatments (Qian et al., 2012). 
Nonetheless, no interventional trials that target pain have been conducted in patients with 
NMOSD. The most significant strength of this study is that it addresses the high unmet need of 
these patients. The controlled study design used to determine efficacy of Scrambler therapy 
allows for specific questions to be answered which will guide future research. Because 
Scrambler therapy has never been rigorously tested for CNP treatment, it would have been 
impractical to test its use in a larger trial without first ascertaining if it is a feasible, safe and 
potentially effective option. We also conducted a parallel study to provide additional context to 
the basis of targeting pain to improve QoL in NMOSD. In a larger cohort of NMOSD, we 
assessed cross-sectional evidence that pain severity impacts components of quality of life, the 
purpose of which was to explore if pain severity may contribute to components that lead to poor 
QoL in patients with NMOSD. The results of these innovative studies provide a strong 
foundation of evidence to support further investigation of Scrambler therapy use for NMOSD, as 
well as other etiologies of CNP.  
 Published evidence for the use of Scrambler therapy is limited. Most research thus far 
involved open label, observational studies (Majithia et al., 2016). Only two previously reported 
studies utilized a blinded, randomized sham-controlled design (Campbell et al., 2013; 
Starkweather et al., 2015). Assessing the feasibility of the sham procedure further informs a 
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larger trial. The current study provides deeper insight into a pragmatic way to provide patients 
with sham intervention, through which patients reported being adequately masked. The sham 
protocol used in this investigation can be adapted for use in any randomized Scrambler trial, 
regardless of the population being studied.    
 This study is not without its limitations. Due to inadequate resources, a third party could 
not be recruited to receive training in and provide Scrambler therapy for this trial. As such, the 
primary investigator served as the Scrambler technician, and was therefore unblinded. To 
mitigate the risk associated with a single-blinded study design, patient-reported outcomes data 
were collected by an independent study coordinator. To further promote study integrity, 
randomization was additionally performed by an independent party. In the future, the data from 
the current study may provide sufficient evidence to facilitate the procurement of resources that 
will enhance the scientific rigor of a larger Phase III trial.  
 Secondly, the Scrambler component of this dissertation was powered for effect at the end 
of the 10-day treatment based on peripheral neuropathy data. While it was encouraging to find 
that this allowed for an adequately powered study to detect a difference between the Scrambler 
treated and sham arms at this time point, the practicality of using Scrambler increases if the 
effect is sustained. In this study, the effect was sustained at the 30-day time point, but not at the 
60-day time point. Re-emergence of pain has been described in open-label, observational studies, 
in treatment of both peripheral and central pain conditions (Smith et al., 2017; Mealy et al., in 
press). Data suggest that pain continues to be amenable to subsequent treatment, often with fewer 
Scrambler treatment sessions needed (Smith et al., 2017). Nonetheless, powering a larger Phase 
III study with a primary endpoint for effect at 60 days rather than at end of treatment would 
increase the study rigor, practicality and appeal of Scrambler treatment. A post hoc calculation 
PAIN IN NMOSD   
124 
 
was conducted to determine how to power a Phase III trial with this change in primary outcome 
and indicated that 29 patients per arm would be sufficient to show such an effect.  
Implications for Nursing 
A primary purpose of nursing research is to provide evidence-based research that 
promotes quality health outcomes for patients. Despite being one of the most common medical 
complaints, pain is often unrelieved and undertreated (McCarberg, Nicholson, Todd, Palmer, & 
Penles, 2008). With its physical, psychological, and economic impact, it is well-documented that 
pain affects QoL. Alleviating suffering and enhancing QoL is in direct alignment with nursing 
research. As such, the implications of the current study for nursing research are clear. 
The current study was informed by TOUS (Lenz et al., 1997), which postulates that co-
occurring symptoms are both influenced by and influence physiologic, psychologic, and 
situational factors, and that the interaction among these factors impacts performance. The 
discovery that patients who report moderate to severe pain were more likely to endorse lower 
functioning, more anxiety and more sleep disturbance supports the underpinning of this theory. 
This adds credence to the practicality of this model for use in nursing research that involves 
symptom co-occurrence and helps to refine its application. Although only pain was directly 
intervened on, the indication that there are indirect effects on other symptoms may make this 
intervention more clinically meaningful to patients. This concept is supported by research 
involving activation of the HPA axis, which shows that pain results in increased cortisol levels, 
which is associated with mood disorders (Gerrits et al. 2014). Improving functional status and 
QoL may afford patients with opportunities to engage in richer lives socially, personally and 
professionally in the context of significant pain reduction, and Scrambler may enable that in a 
non-invasive way. To date, medical research in NMOSD has primarily focused on disease 
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suppression and cure. Nursing research provides the unique opportunity to advocate for patients 
by recognizing the impact symptoms have on QoL and exploring remediation. 
From a practical standpoint, the suggestion based on these data that a simple numeric 
rating of pain may act as an adequate surrogate of pain interference and components of QoL is a 
valuable finding that merits further validation. This can be easily captured by health care 
providers, even in the course of a busy day, but is only of value if targeting this number might 
translate into a clinically meaningful change in the function of patients with NMOSD.        
Recommendations for Future Research  
The primary focus of this dissertation was to capture data that can inform a larger trial 
toward the effort of alleviating pain in this severely affected population. The data obtained from 
this study establish an exciting foundation for future evaluation of Scrambler use in this 
population. The evidence suggests that 1) targeting pain may impact QoL, and 2) Scrambler 
therapy is an effective and safe non-invasive treatment for pain in patients with NMOSD. As 
such, a Phase III trial that is better powered to address sustainability of treatment and effect on 
co-occurring symptoms and QoL over time is warranted, particularly given that effects on sleep 
may emerge due to activation of the HPA axis, but may be delayed. Because of the subjectivity 
of patient-reported outcomes, such a study would benefit from combining patient-reported 
outcomes with objective measures such as changes in serum and salivary biomarkers of 
inflammation and pain in response to Scrambler therapy. Lastly, a larger trial would provide an 
opportunity to implement a study design that clarifies how to protocolize treatment of re-
emergence of pain with subsequent treatments for sustained effect. Because of the rarity of the 
diagnosis, engaging multiple sites for patient recruitment in a larger trial may be warranted. 
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Given that response can vary based on the technician delivering treatment (Moon et al., 2015), it 
would be important to implement systematic and consistent training across all sites. 
Another area of future research could be aimed at instrument development specific to this 
population, as well as validation of instruments that currently exist. At this time, no instruments 
have been developed and/or validated for use in patients with NMOSD. Because the symptoms 
themselves, as well as the psychosocial impact of these symptoms on QoL, are unique to any 
disease, ensuring that instruments adequately capture the patient experience is necessary. 
Lastly, this research suggests that patients with NMOSD are no more anxious or 
depressed than general U.S. populations. This suggests that these patients display remarkable 
resiliency despite being faced with terrible disability and uncertain futures. Developing a deeper 
understanding of whether this signal of resiliency is accurate and what contributes to this 
resiliency would be an interesting topic for future research. Given that NMOSD is a rare disease, 
there tends to be an active community of patients who are involved in advocacy groups and 
online support groups. Recruitment for Aim 3 involved soliciting patients in such a group, 
though only 12 of the 72 were recruited from this source. Nonetheless, many others who were 
recruited through the Hopkins NMO Clinic are also involved in such organizations. Investigating 
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Scrambler study inclusion & exclusion criteria 
 
Inclusion Criteria Exclusion Criteria 
Diagnosis of NMOSD Relapse within 6 months prior to 
enrollment 
AQP-4 seropositivity  Diagnosis of peripheral neuropathy 
>18 years of age Ongoing concomitant CNS disorder 
Persistent pain (>3 months) rated at 
>4 on NRS pain scale 
Patients who have used 
investigational agents or treatments 
for pain control within 30 days 
CNP referable to lesion starting at or 
below C4  
Pregnant or breastfeeding women 
Stable medication regimen for > 30 
days prior to enrollment 
Cognitive or mental incompetence  
Able to read and understand English Patients with implantable devices 
  




Scrambler study patient event calendar 
 
Phase Screening/Consent Scrambler Therapy or Sham 
Treatment (Treatment Phase) 
Follow-up (days) 
Time Point 







Exam/Tests* Neurologic Exam, MRI review, Q# 
AE and daily NRS pain score 
assessment during treatment 
phase (days 1-10) 
Q# NRS pain score, Q# 
NRS pain 
score, Q# 
#Q: Questionnaires (BPI; Neuro-QoL SF, – anxiety, – depression,– sleep disturbance) 
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and Informant Reports of Executive Functioning in Neuromyelitis Optica. Poster presentation at 
the annual conference of the American Academy of Neurology (AAN). Washington, DC. 
21. Mealy MA, Cook LJ, Pache F, Borisow N. Velez DI, Becker D, Jimenez Arango JA, Paul F, Levy M. 
(2015, October). Do Vaccinations Trigger Relapses in Neuromyelitis Optica? Poster presentation 
at the annual conference of the European Committee for Treatment and Research in Multiple 
Sclerosis (ECTRIMS). Barcelona, Esp. 
22. Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD, Thompson CB, Pardo CA, 
Calabresi PA, Levy M, Izbudak I. (2015, October). Differentiating neuromyelitis optica from other 
causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging. 
Poster presentation at the annual conference of the European Committee for Treatment and 
Research in Multiple Sclerosis (ECTRIMS). Barcelona, Esp. 
23. Orman G, Pekcevik Y, Thompson C, Mealy M, Levy M, Izbudak I. (2015, October). Brain contrast 
enhancement in neuromyelitis optica: its relation to acute attacks and clinical disease severity. 
Poster presentation at the annual conference of the European Committee for Treatment and 
Research in Multiple Sclerosis (ECTRIMS). Barcelona, Esp. 
24. Orman G, Pekcevik Y, Thompson C, Siddique L, Mealy M, Levy M, Izbudak I. (2015, October). 
Longitudinal evolution of neuromyelitis optica brain lesions on MRI and correlation to disability 
scores. Poster presentation at the annual conference of the European Committee for Treatment 
and Research in Multiple Sclerosis (ECTRIMS). Barcelona, Esp. 
25. Mealy MA, Button J, Al-Louzi O, Orman G, Jazebi N, Izbudak I, Calabresi PA, Saidha S, Levy M. 
(2016, April). MRI Lesion Length in Acute Optic Neuritis Correlates with Degree of Inner Retinal 
Thinning in Multiple Sclerosis. Poster presentation at the annual conference of the American 
Academy of Neurology (AAN). Vancouver, CA. 
26. Bove R, Elsone L, Alvarez E, Borisow N, Cortez M, Mateen F, Mealy M, Sorum J, Mutch K, Tobyne 
S, Ruprecht K, Buckle G, Levy M, Wingerchuk D, Friedemann P, Cross A, Weinshenker B, Jacob A, 
Klawiter E, Chitnis T. (2016, April). Hormonal Exposures Relate to Clinical Phenotype in Women 
with Neuromyelitis Optica. Poster presentation at the annual conference of the American 
Academy of Neurology (AAN). Vancouver, CA. 
27. Schwartz K, Mealy MA, Levy, M. (2016, April). Treatment of Acute Relapses in Transverse 
Myelitis: Steroids Alone Versus Steroids Plus Plasma Exchange. Poster presentation at the 
annual conference of the American Academy of Neurology (AAN). Vancouver, CA. 
28. Mealy MA, Yeshokumar A, Mossburg SE, Levy M. (2016, April). Long Term Disability in 
Neuromyelitis Optica Spectrum Disorder Is Associated with Number of Relapses, MRI Lesion 
Length and Race. Poster presentation at the annual conference of the American Academy of 
Neurology (AAN). Vancouver, CA. 
29. Abboud H, Rossman I, Mealy M, Levy M. (2016, April). Rates of True Positives and False Positives 
in Paraneoplastic Antibody Testing in Neurological Diseases. Poster presentation at the annual 
conference of the American Academy of Neurology (AAN). Vancouver, CA. 
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30. Mealy MA,* Chavarro VS,* Pache F, Lacheta A, Ruprecht K, Simpson A, Paul F, Brandt A, Levy M. 
(2016, April). Pain, Fatigue and Depression in Patients with Neuromyelitis Optica Spectrum 
Disorder in Europe and USA. Poster presentation at the annual conference of the American 
Academy of Neurology (AAN). Vancouver, CA. 
31. Kessler R, Mealy MA, Levy M. (2016, April). Early Predictors of Relapses versus Pseudorelapses 
in Neuromyelitis Optica Spectrum Disorder. Poster presentation at the annual conference of the 
American Academy of Neurology (AAN). Vancouver, CA. 
32. Mealy MA, Simpson A, Levy M. (2016, September). Comparing the Burden of Symptom Severity 
among Autoimmune Diseases affecting the Spinal Cord. Poster presentation at the annual 
conference of the European Committee for Treatment and Research in Multiple Sclerosis 
(ECTRIMS). London, UK. 
33. Zackowski KM, Schwartz K, Wymbs N, Huang H, Jiang A, Becker D, Celnik PA, Pardo CA, Mealy 
MA, Levy M. (2016, September). Phase II, placebo-controlled, double-blinded, crossover study 
of dalfampridine-extended release (D-ER) in monophasic transverse myelitis. Poster 
presentation at the annual conference of the European Committee for Treatment and Research 
in Multiple Sclerosis (ECTRIMS). London, UK. 
34. Levy M & Mealy MA. (2016, September). Phase I, Open Label Safety Study of Ublituximab for 
the Treatment of Acute Neuromyelitis Optica Relapses. Poster presentation at the annual 
conference of the European Committee for Treatment and Research in Multiple Sclerosis 
(ECTRIMS). London, UK. 
35. Kessler RA, Mealy MA, Jimenez-Arango JA, Quan C, Paul F, López R, Hopkins S, Levy M. (2016, 
September). Anti-Aquaporin-4 Titer Is Not Predictive of Disease Course in Neuromyelitis Optica. 
Poster presentation at the annual conference of the European Committee for Treatment and 
Research in Multiple Sclerosis (ECTRIMS). London, UK. 
36. Cook LJ, Rose JW, Alvey J, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, Dean 
JM , Han MH, Feng M, Ganaway T, Levy M, Mealy M… Behne J. (2016, September). A 
comparison of seropositive and seronegative patients in the Collaborative International 
Research in Clinical and Longitudinal Experience for NMOSD Studies (CIRCLES) registry. Poster 
presentation at the annual conference of the European Committee for Treatment and Research 
in Multiple Sclerosis (ECTRIMS). London, UK. 
37. Cook LJ, Rose JW, Jolley AM, Alvey J, Kuhn R, Pederson M, Han M, Levy M, Mealy M… Behne J. 
(2016, September). The CIRCLES program: accelerating solutions to neuromyelitis optica 
spectrum disorder. Poster presentation at the annual conference of the European Committee 
for Treatment and Research in Multiple Sclerosis (ECTRIMS). London, UK. 
38. Mealy MA, Kim S, Schmidt F, Lopez R, Jimenez Arango JA, Paul F, Wingerchuk DM, Greenberg 
BM, Kim HJ, Levy M. (2017, April). Aquaporin-4 serostatus does not predict response to 
immunotherapy in neuromyelitis optica spectrum disorders. Platform presentation at the annual 
conference of the American Academy of Neurology (AAN). Boston, MA. 
39. Ng JC, Coleman J, Ospina J, Levy M, Mealy MA. (2017, April). Treatment of acute NMO relapses: 
Earlier does not necessarily mean better. Poster presentation at the annual conference of the 
American Academy of Neurology (AAN). Boston, MA. 
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40. Kessler RA, Mealy MA, Levy M. (2017, April). Clinical predictors of death in neuromyelitis optica 
spectrum disorder. Poster presentation at the annual conference of the American Academy of 
Neurology (AAN). Boston, MA. 
41. Gordon-Lipkin E, Mealy MA, Ferenc L, Ryan M, Levy M, Arenivas A. (2017, April). 
Neuropsychological Profiles in Pediatric Neuromyelitis Optica Spectrum Disorder. Poster 
presentation at the annual conference of the American Academy of Neurology (AAN). Boston, 
MA. 
42. Kessler RA, Schwartz, Li X, Mealy MA, Levy M. (2017, April). Two-Year Observational Study of 
Deferiprone in Superficial Siderosis. Poster presentation at the annual conference of the 
American Academy of Neurology (AAN). Boston, MA. 
43. Pardo S, Mealy MA, Nam T, Burns KH, Levy M. Familial Transverse Myelitis Associated with 
Mutation in VPS37A Gene. (2017, April). Platform presentation at the annual conference of the 
American Academy of Neurology (AAN). Boston, MA. 
44. Mealy MA, Cook LJ, Pache F, Borisow N, Velez-Sierra DL, Becker D, Jimenez Arango JA, Paul F, 
Levy M. (2017, October). Vaccines and the risk of relapse in patients with neuromyelitis optica 
spectrum disorder. Poster presentation at the annual conference of the European Committee 
for Treatment and Research in Multiple Sclerosis (ECTRIMS). Paris, FR. 
45. Banerjee A, Coleman J, Ng JC, Ospina J, Mealy MA, Levy M. (2017, October). Point of no return: 
outcomes from acute relapses of neuromyelitis optica depend on severity. Poster presentation 
at the annual conference of the European Committee for Treatment and Research in Multiple 
Sclerosis (ECTRIMS). Paris, FR. 
46. Mealy MA, Cabahug P, Levy M. The Effect of Sexual Dysfunction on Quality of Life in Women 
with Neuromyelitis Optica Spectrum Disorder. (2018, April). Poster presentation at the annual 
conference of the American Academy of Neurology (AAN). Los Angeles, CA.  
47. Mealy MA, Munoz Arcos L, Barreras P, Garcia M, Becker D, Newsome SD, Gailloud PH, Levy M, 
Pardo CA. It’s Not All Transverse Myelitis: The Differential Diagnosis of Spinal Cord Myelopathy. 
(2018, April). Platform presentation at the annual conference of the American Academy of 
Neurology (AAN). Los Angeles, CA. 
48. Mealy MA, Mossburg SE, Kim SH, Messina S, Borisow N, Lopez R, Ospina JP, Scheel M, 
Yeshokumar A, Amine A, Jimenez JA, Paul F, Palace J, Kim HJ, Levy M. Contributors to long-term 
disability in patients with neuromyelitis optica spectrum disorder. (2018, April). Poster 
presentation at the annual conference of the American Academy of Neurology (AAN). Los 
Angeles, CA. 
49. Munoz Arcos L, Gordon-Lipkin E, Barreras P, Castaneda MJ, Mealy MA, Piedra W, Murphy O, 
Levy M, Becker D, Newsome SD, Pardo CA. The spectrum of myelopathies in children: Beyond 
idiopathic transverse myelitis. Poster presentation at the annual conference of the American 
Academy of Neurology (AAN). Los Angeles, CA. 
50. Mealy MA, Kozachik SL, Newsome SD, Nolan MT, Smith TJ, Levy M. Scrambler Therapy: 
Potential New Treatment for Central Neuropathic Pain? (2018, June). Poster presentation at the 
annual conference of the Consortium of Multiple Sclerosis Centers. (CMSC). Nashville, TN.  
Extramural Sponsorship 
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9/1/2017-6/1/2018 TL1 TR001078 from the National Center for Advancing Translational Sciences 
(NCATS) a component of the National Institutes of Health (NIH), and NIH 
Roadmap for Medical Research. 
 
Research Coordination 
2007 – 2014  Novartis CFTY720D2309, multi-center Phase III study of fingolimod for daily 
management of multiple sclerosis 
2007 – 2014  Accelerated Cure Project, multi-center longitudinal epidemiologic study looking 
into the causes of demyelinating diseases 
2009 – 2010  Multiple Sclerosis Cognition Study, single-center longitudinal study of cognitive 
dysfunction in multiple sclerosis patients 
2010 – 2011 Multiple Sclerosis Vitamin D Study, single-center pilot study examining the 
safety and effects on immune profile of cholecalciferol on patients with multiple 
sclerosis 
2010 – 2011 Guthy-Jackson Charitable Foundation NMO Consortium, multi-center cohort 
study aimed at characterizing epidemiologic factors in NMO  
2012 – 2015 Dalfampridine in transverse myelitis study in collaboration with Acorda 
Therapeutics, single-center study to test the efficacy of sustained release oral 
dalfampridine in TM 
2013 – 2014 CINRYZE® (C1 esterase inhibitor [human]) for the treatment of acute optic 
neuritis and/or transverse myelitis in neuromyelitis optica and neuromyelitis 
optica spectrum disorder, single-center open-label pilot study to examine the 
safety and efficacy of Cinryze for acute management of neuromyelitis optica 
2013 – 2015 Bevacizumab (Avastin) for the treatment of acute NMO exacerbations in 
collaboration with Genentech and Guthy-Jackson Charitable Foundation, single 
center open-label pilot study to examine the safety and efficacy of bevacizumab 
for the treatment of acute optic neuritis and/or transverse myelitis in 
neuromyelitis optica and neuromyelitis optica spectrum disorder  
2015 – 2017 Ublituximab for the treatment of acute neuromyelitis optica spectrum disorder 
exacerbations in collaboration with TG Therapeutics, single-center open-label 
pilot study to examine the safety and efficacy of ublituximab for acute 
management of neuromyelitis optica exacerbations 
2017 – present Phase II Randomized, Single Blind Sham-Controlled Research Study Investigating 





May 2007 Reviewer, CME/CNE course: Mastering Multiple Sclerosis: Practical Strategies for 
Challenging Cases (Washington, DC) 
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2007 – 2008  Instructor, Clinical Topics in Neuroscience Nursing: Multiple Sclerosis Workshop, 
Department of Neurology and Neurosurgery, Johns Hopkins Hospital (Baltimore, 
MD) 
2009 – 2010  Instructor, National Multiple Sclerosis Society Nurse and Physician Extender 
Training Program: Pediatric Multiple Sclerosis, Department of Neurology, 
University of Texas Southwestern Medical Center (Dallas, TX)  
2011 – 2012  Instructor, NeuroAcademy: Patient Care Management, Transverse Myelitis 
Workshop, Department of Neurology and Neurosurgery, Johns Hopkins Hospital 
(Baltimore, MD) 
Mentoring 
 2009 – 2010 Ana Arenivas, pre-doctoral fellow at University of Texas Southwestern, 
mentored in Pediatric Demyelinating Disease Clinic. Dr. Arenivas is currently a 
PhD neuropsychologist at TIRR Memorial Hermann Institute for Rehabilitation 
and Research in Houston. 
 2015 – 2016  Anusha Yeshokumar, Neurology resident at Johns Hopkins University, mentored 
on a project involving disability in NMO. Dr. Yeshokumar is currently a faculty 
pediatric neurologist at Mount Sinai Health System in New York. 
 2015 – 2017 Jennifer Ng, Master’s in Nursing at Johns Hopkins University, mentoring for 
Research Honors Program with NMOSD project, for which results were 
presented at the American Academy of Neurology. Ms. Ng is currently employed 
in the Neonatal ICU in Children's Memorial Hermann Hospital.  
 2016 – 2017 Juan Pablo Ospina, Medical Student at Universidad el Bosque, mentored during 
clinical rotation at Johns Hopkins University Department of Neurology on a 
project involving disability and treatment in NMO.  
 2016 – present Kate Schwartz, Licensed Practical Nurse at Johns Hopkins University, act as her 
direct supervisor for clinical trials including Dalfampridine in Transverse Myelitis 
and Eculizumab in NMO. 
 2018 – present Lauren Totonis, Master’s in Nursing at Johns Hopkins University, mentoring for 
Research Honors Program with NMOSD project involving symptom co-




1999 – present  Nursing License, State of Maryland, license #: R145581 
2003 – 2009 Certified Neurologic Registered Nurse (CNRN) 
2009 – present    Multiple Sclerosis Nurses International Certification (MSCN) 
2014 – present Rare Neuroimmunologic Disorders Certification (CRND) 




July 2007 Medical Advisor, Transverse Myelitis Association Family Camp, Victory Junction 
Gang Camp (Randleman, NC) 
July 2013 Medical Advisor, Transverse Myelitis Association Family Camp, the Center for 
Courageous Kids (Scottsville, KY) 
August 2014 Medical Advisor, Johns Hopkins Transverse Myelitis Center Adventure Camp, 




Journal Peer Review activities: 
Annals of Neurology, 2015 
JAMA Neurology, 2017  
Journal of the Neurological Sciences, 2017 – 2018 
Multiple Sclerosis and Related Disorders, 2018 
International Journal of Multiple Sclerosis Care, 2018 – 2019 
Elected and Appointed Board and Committees Memberships  
2014 – present Inaugural Board Member, Certified Rare Neuroimmunologic Diseases, 
Consortium of Multiple Sclerosis Centers 
2016 – present  Focus Group Member, Continuing Professional Education Committee, 
Consortium of Multiple Sclerosis Centers 
2016 – present Research Committee Member, International Organization of Multiple Sclerosis 
Nurses 
2017 – present  Board of Directors, International Organization of Multiple Sclerosis Nurses 
2018 – present NMO International Clinical Consortium Member, Guthy Jackson Charitable 
Foundation 
2018 – present Research Committee Co-Chair, International Organization of Multiple Sclerosis 
Nurses 
Professional Societies 
1994 – 1996 Order of Omega Leadership Fraternity 
1999 – present  Sigma Theta Tau International Honor Society of Nursing 
2007 – present International Organization of Multiple Sclerosis Nurses 
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2008 – present Consortium of Multiple Sclerosis Centers 
2010 – present American Academy of Neurology 
Conference Organizer/Session Chair 
June 2013 Johns Hopkins Transverse Myelitis Center Patient Symposium, Organizer 
June 2014 Johns Hopkins Transverse Myelitis Center Patient Symposium, Organizer 
October 2014 Johns Hopkins Neuromyelitis Optica Patient Day, Organizer 
June 2015 Johns Hopkins Transverse Myelitis Center Patient Symposium, Organizer 




May 2010 Consortium of Multiple Sclerosis Centers Scholarship  
May 2017 Sigma Theta Tau International Honor Society of Nursing Research Award 
September 2017 TL1 Trainee Award through the Johns Hopkins Institute for Clinical and 
Translational Research Predoctoral Clinical Research Training Program (PCRTP), 
funded by the National Institutes of Health 
April 2018 Burroughs Wellcome Fund Trainee Award on behalf of the Translational Science 
2018 Program Committee 
April 2018 TL1 Blue Ribbon Poster Award at Translational Science 2018 Annual Meeting 
Invited Talks 
September 2010 Invited Speaker, Rare Neuroimmunologic Disorder Symposium, University of 
Texas Southwestern Medical Center (Dallas, TX) 
February 2011 Journal Club Facilitator, “Freedom From Disease Activity in Multiple Sclerosis”, 
Multiple Sclerosis Association of America (New Orleans, LA) 
April 2011 Invited Speaker, Multiple Sclerosis 101, Multiple Sclerosis Association of America 
(Springfield, MO) 
November 2011 Expert Panel Participant, Annual Conference and Bernice Schacter Research 
Symposium, National Multiple Sclerosis Society, Delaware Chapter (Newark, DE) 
November 2013 Invited Speaker, Updates on Neuromyelitis Optica, International Organization of 
Multiple Sclerosis Nurses (online webinar) 
October 2014 Invited Speaker, Neuromyelitis Optica: Symptom Management, Johns Hopkins 
Neuromyelitis Optica Patient Day (Baltimore, MD) 
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May 2015 Invited Speaker, Neuromyelitis Optica: Diagnosis and Treatment, Consortium of 
Multiple Sclerosis Centers Annual Meeting (Indianapolis, IN) 
August 2015 Invited Speaker, Pain in NMO, Johns Hopkins Neuromyelitis Optica Patient Day 
(Baltimore, MD) 
June 2016 Invited Speaker, Neuromyelitis Optica Spectrum Disorder: Diagnosis, 
Epidemiology and Management, Consortium of Multiple Sclerosis Centers 
Annual Meeting (National Harbor, MD) 
June 2016 Invited Speaker, How to Navigate the Healthcare Team, Johns Hopkins 
Transverse Myelitis Center Patient Symposium (Baltimore, MD) 
December 2016 Invited Speaker, Pain in Neuromyelitis Optica Spectrum Disorder, Harvard 
Medical School Neuromyelitis Optica Patient Day (Boston, MA) 
May 2017 Invited Speaker, Neuromyelitis Optica Spectrum Disorder: Diagnosis, 
Epidemiology and Management, Consortium of Multiple Sclerosis Centers 
Annual Meeting (New Orleans, LA) 
October 2017 Invited Speaker, Neuromyelitis Optica Spectrum Disorder and Optic Neuritis, 
Transverse Myelitis Association Rare Neuro-Immune Disorders Symposium 
(Columbus, OH) 
October 2017 Invited Speaker, Recognizing and Treating Neuropathic Pain, Transverse Myelitis 
Association Rare Neuro-Immune Disorders Symposium (Columbus, OH) 
October 2017 Invited Panelist, Neuropathic Pain, Transverse Myelitis Association Rare Neuro-
Immune Disorders Symposium (Columbus, OH) 
October 2017 Invited Speaker, Are New Drugs on the Horizon for NMOSD?, Transverse Myelitis 
Association Rare Neuro-Immune Disorders Symposium (Columbus, OH) 
March 2018 Invited Panelist, Ask the Expert, Guthy Jackson Charitable Foundation 
Neuromyelitis Optica Patient Day (Los Angeles, CA)  
April 2018 Invited Speaker, Improving NMO Patient Quality of Life, Guthy Jackson 
Charitable Foundation Academic Neuromyelitis Optica Roundtable Meeting (Los 
Angeles, CA) 
 
